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Matthew Jose Justice 
HOMEOSTATIC ROLE OF ACID SPHINGOMYELINASE IN MTOR SIGNALING 
AND AUTOPHAGY 
Key regulatory decisions of protein synthesis and autophagy are controlled by 
the lysosomal nutrient sensing complex (LYNUS). To engage protein synthesis 
signaling, LYNUS requires cellular availability of amino acids, adenosine 
triphosphate (ATP), growth factors, and docking at the lysosomal membrane. 
The molecular determinants of LYNUS signaling and docking are not completely 
elucidated and may involve regulators of the lipid membrane structure and 
function of the lysosome. Since ceramides are both bioactive second 
messengers and determinants of lipid membrane stiffness, we investigated the 
role of the ceramide-producing lysosomal acid sphingomyelinase (ASM) in the 
homeostatic function of mammalian target of rapamycin (mTOR) signaling and 
autophagy. Using ASM inhibition with either imipramine or siRNA against 
SMPD1, in primary human lung cells or Smpd1+/- mice, we demonstrated that 
ASM is an endogenous inhibitor of autophagy. ASM was necessary for 
physiological mTOR signaling and maintenance of sphingosine levels. Whereas 
overstimulation of ASM has been shown to trigger autophagy with impaired flux, 
inhibition of ASM activity during homeostatic, non-stressed conditions triggered 
autophagy with degradative potential, associated with enhanced transcription 
factor EB (TFEB), a master regulator of autophagy and lysosomal biogenesis 
genes, translocation to the nucleus and decreased sphingosine levels. These 
findings suggest LYNUS signaling and autophagy are partially regulated by ASM. 
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Chapter 1. Introduction 
1.1 Relevance 
Acid sphingomyelinase (ASM), a phosphodiesterase that hydrolyzes 
sphingomyelin to produce ceramide and phosphorylcholine, is most notably 
known for its role in Niemann-Pick disease (NPD), a lysosomal storage disorder 
that has recently been shown to involve aberrant autophagy as part of its 
pathogenesis (Figure 1).1 Niemann-Pick type A patients have little to no ASM 
activity and usually die during infancy, while type B patients have about 10% of 
normal ASM activity and may survive into the second decade of life.2 
Sphingomyelin buildup in lysosomes due to decreased hydrolysis by ASM leads 
to permeabilization of the lysosomal encapsulating membrane and subsequent 
release of cathepsin B (a lysosomal cysteine protease) thereby digesting 
cytosolic proteins needed for cellular function.1 Sphingomyelin overload also 
causes dysregulated autophagy, a process that degrades a portion of the 
cytoplasm in order for the cell to survive during times of nutrient-deprivation—this 
process will be explained in depth later in the introduction.1, 3 In the last decade, it 
has come to light that a number of other diseases exhibit dysregulation of ASM 
coupled with altered autophagy 4-8. However, outside of the context of hypo- or 
hyper-activation of ASM in disease states, very little is known about the 
homeostatic function of ASM.5 This thesis sets out to understand the basal role 
of ASM in homeostatic conditions as it pertains to autophagy. Since autophagy is 
a process that is signaled by complexes that are anchored to the lysosome, a  
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Figure 1. 
 
 
Substrate and products of ASM. 
ASM is a phosphodiesterase that utilizes a water molecule to effectively 
cleave the ester bond of sphingomyelin, producing ceramide (ceramide 18:1 
shown) and phosphorylcholine. A space filling model (the size of the sphere is 
representative of the atomic radius of the atom) of the molecules is shown. 
Carbons are in gray, hydrogens in white, nitrogens in blue, oxygens in red, and 
phosphori in fuchsia. 
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parameter partially controlled by lipid content of the lysosomal membrane bilayer, 
ASM may be important in the baseline control of this process.5, 9, 10  
The work contained herein investigates how acid sphingomyelinase acts to 
regulate autophagy. We will demonstrate that ASM is required for signaling by 
mammalian target of rapamycin (mTOR), an endogenous inhibitor of autophagy, 
and, thus, plays a major role in the induction of autophagy. The exact mechanism 
for this regulation was not elucidated, but may be related to the lysosomal 
membrane permeable metabolite of ceramide, sphingosine.  
1.2 Autophagy 
“Self-eating” is the literal Latin-to-English translation of the term autophagy, 
which was coined by Christian de Duve at the 1963 Ciba Foundation Symposium 
on Lysosomes, during which he proposed the renaming of Alex Novikoff’s 
cytolysomes to autophagic vacuoles.11 In times of nutrient and energy deprivation 
during the life of a cell, autophagy is the process that allows the cell to continue 
to function by digesting and reallocating a portion of its cytoplasmic contents in 
an effort to return to an overall replete state (Figures 2 and 3).3 The autophagic 
process involves several proteins that work in concert, both spatially and 
temporally, to produce an intracellular store of accessible nutrients when none 
are available.12 There are three modes of autophagy: micro-autophagy, 
chaperone-mediated autophagy, and macro-autophagy. All three modes involve 
sequestration of cytoplasmic contents, fusion with a lysosome, and degradation 
within the newly generated compartment.13 
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Figure 2. 
 
Nutrient Replete State. 
During times of nutrient plentitude, protein synthesis occurs and autophagy is 
not necessary for the cell to survive. Graphic representation of a cell and its 
organelles, which are indicated with text, color, and shape. 
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Figure 3. 
 
Nutrient deplete state. 
During times of starvation, the autophagic process is induced and 
autolysosomes are formed. Digestion of autolysosomal contents produces 
nutrients that are distributed back to the cell for survival. Graphic representation 
of a cell and its organelles, which are indicated with text, color, and shape. 
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Micro-autophagy refers to an autophagic process in which cytoplasmic 
contents fuse directly with the lysosome in order to be degraded (Figure 4). In the 
lysosomal membrane, regions of high lipid content and low protein content allow 
segments of the membrane to lend themselves to invagination.14 These 
microdomains are the sites of micro-autophagic tubule formation, an ATP-
dependent process.15 The tubule elongates, protruding into the lysosomal lumen 
and drawing the cytoplasmic contents inward. Scission then occurs, trapping the 
tubule inside the lysosome, where it is degraded by lysosomal hydrolases. Once 
the contents are degraded, permeases release the energy and nutrients back 
into the cytosol. This process can engulf both nonspecific and specific 
substrates, with the latter being the case for the sub-classifications of micro-
autophagy of peroxisomes (micropexophagy), micro-autophagy of mitochondria 
(micromitophagy), micro-autophagy of the ER (ER-phagy), and micro-autophagy 
of nuclei (piecemeal micro-autophagy of the nucleus).16 
Chaperone-mediated autophagy is an autophagic process in which specific 
proteins that contain a particular recognition motif are targeted for degradation 
and are delivered to lysosomes in, as the name implies, a chaperone-mediated 
fashion (Figure 5).17 The recognition motif of a protein to be degraded is a 
prerequisite for this type of autophagy and can be formed or exposed by either 
posttranslational modifications or disassembly of complexes. Heat shock protein 
70, along with other co-chaperones, recognize and transport the cargo to the 
lysosomal membrane. At the lysosomal membrane, lysosome-associated 
membrane protein 2A (LAMP2A) accumulates and facilitates the unfolding of the   
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Figure 4. 
 
Microautophagy. 
Cytosolic contents directly enter the lysosome through invaginations that are 
caused by differing local lipid/protein contents. After elongation of the tubule, 
scission occurs, segregating the tubule from the cytosol. The contents of the 
tubule are then digested for purposes of reallocation. Graphic representation of a 
lysosome digesting organelles, which are indicated with color and shape (inside 
of tubule which is indicated with blue). 
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Figure 5. 
 
Chaperone-mediated autophagy. 
Proteins with certain recognition motifs are recognized by chaperone proteins, 
which traffic them to lysosome, where other chaperones and lysosome-
associated proteins facilitate the unfolding of the protein as well as the crossing 
of the lysosomal membrane bilayer. Graphic depiction of a protein being 
unfolded, crossing the lysosomal membrane, and subsequently being degraded. 
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cargo protein for transit across the lysosomal membrane. Heat shock protein 90, 
on the luminal side of the lysosome, stabilizes the multiple copies of LAMP2A 
that are required for passage. Once in the lysosome, degradation happens as 
described previously. 
Macro-autophagy, referred to as simply autophagy hereafter, is the most 
studied of the different types of autophagy and will be the only type considered in 
this dissertation. The act of digesting a portion of a cell for the survival of that cell 
may seem rather trivial, but the molecular mechanisms involved in this “simple” 
process are quite intricate. When autophagy is induced, an autophagosome 
forms around the contents to be degraded. An autophagosome must be initiated, 
elongated, and closed before the autophagosome can be delivered to a 
lysosome, where it will then fuse with the lysosome, creating an autolysosome 3. 
Once the outer bilayer of the autophagosome fuses with the bilayer of the 
lysosome, degadative enzymes are released into the autolysosome. This is the 
degradative compartment in which autophagic substrates are broken down for 
release into the cytosol. Several proteins must act in an orchestrated manner for 
this process to occur.12 
Autophagosome formation—specifically, the site(s) where an autophagosome 
forms and the origins of autophagosomal membranes—is the least understood 
aspect of autophagy.12 Several autophagy-related (ATG) proteins take part in the 
initiation of the autophagosome, but only one kinase, Unc-51-like kinase (ULK), 
plays a role in initiation; furthermore, the activity of this kinase is currently known 
to be involved in initiation.12 The pre-autophagosomal structure that will give rise 
10 
to an autophagosome is called the phagophore, or isolation membrane. The 
phagophore has been thought of as a liposome that has been flattened, having 
little or no interior region, thus giving rise to two membrane bilayers that can be 
likened to two pancakes sitting one on top of the other, connected at the edges–
much like the folds of the endoplasmic reticulum (ER). Reports in the literature 
suggest this membrane does originate from ER; however, many different 
membrane sources, such as mitochondria and molecular mechanisms distal to 
the ER, are involved and are necessary for autophagosome formation and 
maturation.18, 19 
The elongation or expansion of the double-bound autophagosomal 
membrane requires two ubiquitin-like conjugation systems: the ATG12-ATG5 
system and the microtubule-associated protein light chain 3 beta-
phosphatidylethanolamine system (LC3B-PE).12 Just like the attachment of 
ubiquitin to a protein requires several steps, ATG12 attachment to ATG5 and 
LC3B attachment to PE—both ubiquitin-like conjugations—do as well. The first 
step in ubiquitin conjugation is when an E1 activating enzyme, in an ATP-
dependent manner, binds ubiquitin. Secondly, the ubiquitin is transferred from 
the E1 activating enzyme to an E2 conjugating enzyme. Lastly, the E2 
conjugating enzyme binds an E3 ligase, which binds the substrate to be 
ubiquitinated, and the ubiquitin is then transferred to the substrate. The ATG12-
ATG5 system is required for elongation of the autophagosomal membrane and is 
the E3 ligase-like component of the LC3B-PE system. Both systems utilize ATG7 
as the E1-like activating enzyme. For the ATG12-ATG5 complex, the terminal 
11 
glycine of ATG12 is attached to a cysteine on ATG7 in an E1-like manner. Then 
ATG7 is switched out for ATG10 in an E2-like manner. ATG12 is then bound to 
ATG5, which binds ATG16 in an E3-like manner, forming the ATG12-ATG5-
ATG16 complex, which serves as the E3 ligase-like component for the 
phosphoethanolamine lipidation of LC3B. The LC3B protein is produced in a pro-
form that has a terminal arginine, which can be cleaved by ATG4, leaving a 
terminal glycine that can be lipidated in an ubiquitin-like manner. This form of 
LC3B is referred to as LC3B-I. When autophagy is signaled, the ATG7 enzyme 
then activates LC3B-I; subsequently ATG3, the E2-like enzyme for this system, 
switches out with ATG7. Then ATG3 interacts with the E3-like ATG12-ATG5-
ATG16 complex, which covalently links LC3B-I to phosphoethanolamine in the 
membrane of the phagophore. LC3B-I bound to phosphoethanolamine is known 
as LC3B-II, the most widely accepted marker of autophagosomes. Once the 
autophagosome is closed, the ATG12-ATG5 machinery dissociates from the 
autophagosome. 
When the autophagosome is formed, it has to be trafficked to a lysosome. 
The largely accepted mode of transport is via the dynein/dynactin system of 
movement upon microtubules.20 When the autophagosome arrives at the 
lysosome, fusion of the outer membrane of the autophagosome with the 
lysosome must occur in order to make an autolysosome. The transport of 
autophagosomes to lysosomes is thought to be a calcium-dependent process.4 
Exactly how this process works is largely unknown, but it does not depend on 
lysosomal acidification.21 Once an autolysosome is formed, the contents are 
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degraded in a normal fashion by lysosomal hydrolases and proteinases. These 
resultant, fundamental building blocks are distributed back to the cytosol via 
permeases in the lysosomal membrane. Upon degradation of the autolysosome, 
LC3B-II encounters ATG4, which removes the phosphoethanolamine moiety 
from LC3B-II, thus returning it to LC3B-I and dissociating it from the 
autolysosomal membrane. The process in toto, from initiation to distribution of 
reallocated essentials, is known as fluxing autophagy–a truly dynamic event.22 
1.3 LYNUS Complex/mTOR Signaling 
There are two distinct complexes, with different functions, in which mTOR is 
present, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).23 The 
substrate specificity of the complexes are determined by regulatory-associated 
protein of mTOR (RAPTOR), which is specific to mTORC1, and rapamycin- 
insensitive companion to mTOR (RICTOR), which is specific to mTORC2. While 
mTORC2 has role in the regulation of Akt signaling, an upstream mediator of 
mTORC1, only mTORC1 plays a role in inhibiting autophagy. Henceforth, mTOR 
will refer to that which resides in mTORC1 and not that of mTORC2.The ULK1 
complex was mentioned earlier as the most upstream step in the initiation of 
autophagosome formation. The ULK1 complex consists of ULK1, ATG13, and 
FIP200.24 ULK1 has several phosphorylation sites that determine its kinase 
activity. Some of these sites, such as the ones phosphorylated by the 
serine/threonine kinase mTOR, inhibit the kinase ability of ULK1.25 When the 
inhibitory sites are not phosphorylated, ULK1 can auto-phosphorylate different 
sites, greatly increasing its kinase ability. When this happens, ULK1 
13 
phosphorylates both ATG13 and FIP200, causing translocation of the ULK1 
complex from the LYNUS to ER, initiating autophagy. 
The LYNUS is docked at the lysosomal membrane and serves as the 
metabolic sensor for the cell (Figure 6 and 7).9 It senses the nutrient status of the 
cell and promotes protein synthesis during nutrient plentitude and increases 
autophagy during times of nutrient deprivation. This complex is capable of 
sensing the availability of amino acids to the cell, the ATP levels in the cell, and 
whether or not growth factors are present outside of the cell. If glutamine, 
arginine, and/or leucine as well as ATP and growth factor signaling are present, 
and the LYNUS is docked at the lysosome, the LYNUS favors mTOR 
activation.26 If any one of these conditions is not met, the LYNUS deactivates 
mTOR and autophagy increases. 
In order to accurately incorporate growth cues and survey the energy and 
nutrient status of the cell, the LYNUS transduces signals from several different 
proteins, both within the complex as well as externally.27 The Ragulator, upon 
sensing amino acids, translocates and helps anchor mTOR from its cytosolic 
location to the LYNUS.9 The Ras homolog enriched in brain (RHEB) is a guanine 
triphosphate phosphatase (GTPase) that localizes to the lysosome where it binds 
and enhances mTOR activity.28 RHEB is inhibited by the TSC1/2 complex which 
receives growth cues from external growth factors via the Akt pathway and is 
necessary for mTOR activity. 9, 29 RHEB also helps to anchor the LYNUS 
complex to the lysosomal membrane through farnesylation, which involves 
protrusion of a carbon chain moiety into membrane bilayers.28, 30 Deciphering of   
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Figure 6.  
 
 
LYNUS signaling in nutrient replete conditions. 
If adequate amounts of ATP and amino acids are available and growth factors 
are present, mTOR phosphorylates its downstream substrates, and protein 
synthesis occurs. Graphic depiction of the LYNUS machinery, its proximity to the 
lysosome, and signaling during plentitude of nutrients. 
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Figure 7.  
 
 
LYNUS signaling in nutrient deplete conditions. 
If ATP or amino acids are not available or growth factors are not present, 
protein synthesis will not occur, and autophagy will ensue. Graphic depiction of 
the LYNUS machinery, its proximity to the lysosome, and signaling during 
absence of nutrients.  
16 
growth factor signaling and the energy status of the cell happens via LYNUS. 
Together, these proteins sense the needs of the cell and activate signaling 
complexes accordingly. 
The Ragulator consists of five proteins, p18, p14, MP1, HBXIP, and C7orf59, 
which effectively function as a guanine nucleotide exchange factor (GEF) for the 
Rag GTPases, Rag A, Rag B, Rag C, and Rag D.31 A GTPase is able to 
hydrolyze guanine triphosphate (GTP) to guanine diphosphate (GDP), which 
switches cascade signaling from on to off. To switch signaling cascades from off 
to on, GEFs exchange GDP for GTP. Upon sensing amino acids, the Ragulator 
activates heterodimers of the Rag GTPases, thus recruiting mTOR from a 
cytosolic location to the lysosome, where it can interact with RHEB, which is 
necessary for mTOR activity.32 
When RHEB is located at the lysosome and is in the GTP-bound state, 
mTOR is active. When RHEB-GTP is hydrolyzed by the tuberous sclerosis 1/2 
(TSC1/2) complex to RHEB-GDP, mTOR is no longer active. The TSC1/2 
complex effectively inactivates RHEB by acting as a GTPase-accelerating protein 
(GAP) that constantly associates with RHEB, promoting the hydrolysis of RHEB-
GTP to RHEB-GDP.29 In this way, it acts as an inhibitor to mTOR. The TSC1/2 
complex can incorporate exogenous growth factor signals through transduction 
cascades. For example, when insulin-like growth factor attaches to its receptor, 
the receptor will change conformation and thereby auto-phosphorylate. The 
receptor spans the plasma membrane with the ligand site on the extracellular 
side and the auto-phosphorylation sites on the intracellular side. Phosphorylation 
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stimulates phosphoinositide 3 kinase (PI3k), catalyzing the production of 
phosphatidylinositol 3,4,5 trisphosphate (PIP3) from phosphatidylinositol 3,4 
bisphosphate (PI(4,5)P2). This newly modified lipid activates PDK1, a master 
kinase that phosphorylates protein kinase B (PKB/Akt). PKB can phosphorylate 
TSC2, thus dissociating the TSC1/2 complex and making mTOR active (Figure 
8).23 
Sensing of the cell’s energy status, or adenosine triphosphate (ATP) to 
adenosine diphosphate (ADP) ratio, is an important input to the LYNUS as well. 
When the intracellular ATP:ADP ratio is low, adenosine monophosphate-
activated protein kinase (AMPk) phosphorylates the downstream targets TSC2 
and RPTOR, an mTOR binding protein that also dictates mTOR activity. AMPk  
phosphorylation of RPTOR promotes 14-3-3 binding and suppression of mTOR 
signaling in energy-deprived states.24 
As mentioned previously, mTOR inhibits autophagy via the phosphorylation of 
ULK1 inhibitory sites. When active, mTOR directly phosphorylates transcription 
factor EB (TFEB), a master regulator of lysosomal biogenesis and ATG genes, 
which keeps TFEB sequestered in the LYNUS, rendering it unable to up-regulate 
genes involved in autophagy and lysosomal biogenesis. When mTOR is inactive, 
TFEB is dephosphorylated and autophagy is initiated through ULK1. When TFEB 
is dephosphorylated, it leaves the LYNUS and translocates to the nucleus.27, 33 
When this transcription factor translocates to the nucleus, it up-regulates the 
production of more than a dozen genes. It is responsible for the up-regulation of 
itself, genes involved in autophagy, and genes involved in lysosomal biogenesis.  
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Figure 8. 
 
External growth factor signaling cascade. 
Extracellular growth factor signal transduction occurs via an intricate 
mechanism that involves many steps, which culminate in the LYNUS’s decision 
to synthesize proteins or break them down to extract their energy. Graphic 
representation of a cell and its organelles. 
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The switch from nutrient-generating processes to nutrient-depleting 
processes occurs when mTOR is switched from off to on by the mechanisms 
previously described. When active, mTOR phosphorylates P70S6k which 
subsequently phosphorylates ribosomal protein S6 and thus has implications for 
enhancing protein synthesis.  
Another target of mTOR involved in protein synthesis is eukaryotic initiation 
factor 4E binding protein (4E-BP).34, 35 When phosphorylated, 4E-BP dissociates 
from eukaryotic initiation factor 4E (eIF4E) and allows interaction between eIF4E 
and the rest of the eukaryotic initiation factor 4F (eIF4F) complex. The 7-methyl 
guanosine cap of messenger RNA (mRNA) binds to eIF4E, which binds to 
eukaryotic initiation factor 4G (eIF4G), which is a scaffold that connects to poly A 
binding protein (PABP) to bind the poly A tail, promoting circularization and 
translation of mRNA. The LYNUS incorporates the nutrient status of the cell and, 
through mTOR, induces autophagy when nutrients are low. 
1.4 Diagnostic Principles 
To assess the autophagic state of a cell, a set of complementary methods 
need to be employed.22, 36 Although autophagy is highly dynamic, most available 
tools only assess snapshots of this process. Even live microscopy has limitations 
due to decreased resolution and, unfortunately, no live electron microscopy 
techniques exist at this time. It is possible, however, to label proteins with 
molecules that fluoresce and to follow the fluorescent labels over time, inferring 
the underlying actions of the proteins. A combination of endpoints such as 
autophagic protein levels, light images, fluorescent images, electron microscopic 
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images, and mRNA levels are available to assess the autophagic state of a given 
population of cells.22 To rigorously assess autophagy, at least two 
complementary methods and proper controls should be used when assessing 
autophagy. Also, the proper controls to assess autophagic induction versus 
autophagic flux must be incorporated into autophagy experiments. 
As stated previously, the most widely accepted marker of autophagosomes is 
the identification and quantification of lipidated LC3B-II. Often, Western blotting is 
used to probe protein levels of tissue or cells for LC3B-II. Accumulation of LC3B-
II represents increased autophagosome abundance (Figure 9).22, 37 To help 
determine if autophagy is being induced or if autophagic degradation is being 
decreased when an LC3B-II-increasing stimulus is applied, the autophagic flux 
must be assessed. Chloroquine (an anti-malarial agent) is a useful tool to assess 
autophagic flux; this weak base allows assessment by raising lysosomal pH 
through ion-trapping in the lysosome. Another way to raise lysosomal pH without 
utilizing lysosomotropic properties is by inhibiting vacuolar ATPases, such as 
with bafilomycin. Since lysosomal enzymes are pH-dependent, raising the pH of 
the lysosome will inhibit the activity of these enzymes, prevent autophagic cargo 
breakdown, and decrease LC3B-II turnover—known as blockage of the 
autophagic flux (Figure 10).22 The increase of LC3B-II levels when chloroquine 
and stimulus are applied together, above that of stimulus alone, indicate that 
autophagy is being induced.22 If the levels of LC3B-II are the same with stimulus 
in the presence and absence of chloroquine, the autophagic flux is thought to be 
blocked by the stimulus.  
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Figure 9.  
 
LC3B-II accumulation in relation to autophagosome formation and 
degradation. 
When autophagy is induced, the autophagosomal marker LC3B-II is 
incorporated into the phagophore. Increased levels of LC3B-II are present in a 
fully formed autophagosome. Since LC3B-II is turned over in the degradation 
process, decreased levels of LC3B-II are associated with autolysosomes.  
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Figure 10.  
 
Blocked autophagic flux increases LC3B-II levels. 
Autophagosomal marker LC3B-II can be increased in a cell due to either 
increased autophagic induction or decreased autolysosomal degradation. Color 
representation of autophagosome-lysosome fusion. 
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1.5 The Ceramide Pathway 
Ceramide is a bioactive sphingolipid that acts as both a second messenger 
and as an architectural lipid.38, 39 The cell can synthesize ceramide from the de 
novo pathway, the recycling pathway, and the hydrolysis pathway (Figure 11).40 
Downstream metabolites of ceramide, such as sphingosine and sphingosine-1-
phosphate, have crucial signaling roles in the cell as well.41 The generation of 
specific chain length ceramides is also possible.42 
Ceramide is a general term that signifies a class of sphingolipids due to the 
“R” group that exists on this molecule. The “R” group refers to an acyl chain that 
can be of varying length and can contain double bonds. Each ceramide molecule 
contains a carbon chain of 18 carbons with a double bond between carbons four 
and five. The number two carbon has an amide linkage, while the first and third 
carbons have hydroxyl groups. The length of the acyl chain that emanates from 
the amide group determines the exact ceramide species. Acyl chains up to 20 
carbons in length are considered long chain ceramides, while acyl chains of 
greater than 20 carbons are considered very-long chain ceramides. 
The de novo pathway of ceramide generation, which happens in the 
endoplasmic reticulum, utilizes the substrates palmitoyl coenzyme A and an 
amino acid (usually serine), along with the serine palmitoyltransferase enzyme, 
to produce 3-ketosphinganine (Figure 12). This is the rate-limiting step of the 
reaction, i.e., it controls the rate at which ceramide can be made via the de novo  
pathway. The enzyme 3-ketosphinganine reductase acts on 3-ketosphinganine to 
form sphinganine, also known as dihydrosphingosine. Once dihydrosphingosine   
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Figure 11.  
Ceramide synthesis. 
Ceramides can be synthesized in the endoplasmic reticulum via the de novo 
pathway; they can be synthesized from downstream metabolites (recycling); or 
they can be produced rapidly by the hydrolysis of sphingomyelin. Carbons are in 
gray, hydrogens in white, nitrogens in blue, and oxygens in red. 
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Figure 12.  
 
The de novo generation of ceramide. 
Generation of 3-keto-sphinganine occurs when serine and palmitoyl 
coenzyme A are utilized as substrates by serine palmitoyltransferase. This if the 
first step in the synthesis of ceramide and also the rate-limiting step. After 
dihydrosphingosine is synthesized, ceramide synthases, that utilize acyl 
coenzyme A, generate dihydroceramide. The acyl chain length can vary and is 
depicted by an “R” group. Ceramide desaturases insert a double bond to 
generate ceramide. Carbons are in gray, hydrogens in white, nitrogens in blue, 
and oxygens in red. 
  
26 
is formed, ceramide synthase acts on this substrate, producing dihydroceramide. 
Dihydroceramide desaturase utilizes dihydroceramide to produce ceramide. 
Once ceramide is formed, ceramidases are able to convert this molecule into 
sphingosine. Finally, sphingosine kinases can act upon sphingosine to form the 
molecule sphingosine-1-phosphate. This is the most downstream metabolite in 
the ceramide pathway and can be acted upon by sphingosine-1-phosphate lyase 
(S1PL) to form hexadecenal and phosphoethanolamine. The last reaction by 
S1PL is a terminal reaction, as its products permanently exit the ceramide 
pathway. 
The recycling/salvage pathway consists of any route back to ceramide from 
either a ceramide precursor or ceramide metabolite. Most metabolites in the 
ceramide pathway can be converted back to ceramide, including sphingosine, 
ceramide-1-phosphate, glucosyl ceramides, and galactosyl ceramides (Figure 
13). The other route to ceramide production is via the hydrolysis of 
sphingomyelin (Figure 14). 
The enzymes responsible for ceramide generation via the hydrolysis pathway are 
sphingomyelinases, which fall under either category of neutral 
sphingomyelinases (NSMs) or acid sphingomyelinases (ASMs). The different 
groups of sphingomyelinases have different pH optima, spatial distributions 
throughout the cell, and divalent ion dependence. Five mammalian 
sphingomyelin phosphodiesterases (SMPDs) have been characterized to date.43 
SMPD1 is an acidic acid sphingomyelinase and is the focus of this work.44 
SMPD2-4 are neutral sphingomyelinases and correspond to NSM (MA-NSM).45   
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Figure 13.  
The recycling pathway. 
Ceramide is modified by addition or subtraction of certain moieties that can be 
modified in the opposite manner to generate ceramide. Carbons are in gray, 
hydrogens in white, nitrogens in blue, and oxygens in red. 
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Figure 14.  
 
The hydrolysis pathway. 
Sphingomyelin, part of the lysosomal membrane bilayer, can be rapidly 
hydrolyzed to produce ceramide. Carbons are in gray, hydrogens in white, 
nitrogens in blue, oxygens in red, and phosphori in fuchsia. 
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These enzymes work optimally at a pH of around 7. All of the NSMs share the 
characteristic of divalent cation dependence, which Mg2+ or Mn2+ usually 
satisfies. SMPD2 (corresponding to NSM1) is localized and performs its function 
at the endoplasmic reticulum. Little is known about this enzyme, as 
overexpression did not lead to changes in sphingolipid abundance or metabolites 
and SMPD2 knockout mice did not exhibit any phenotypical changes. SMPD3 
(corresponding to NSM2) is a brain-specific enzyme and may preferentially 
produce very-long chain ceramides from very-long chain sphingomyelins.46 The 
location of this enzyme is primarily at the inner leaflet of the plasma membrane, 
but it has been reported to be located at the Golgi apparatus. SMPD4 
(corresponding to NSM3), unlike SMPD2 and SMPD3, does not have 
transmembrane domains but is a C-tail anchored protein.47 The sequence 
identity of SMPD4 has very little in common with SMPD2 or SMPD3 but is highly 
conserved across species. Although SMPD4 is not homologous to SMPD2 or 
SMPD3, it does share functional similarities in that it is able to hydrolyze 
sphingomyelin to produce ceramide and phosphorylcholine.48 There are reports 
in the literature that this enzyme has been found at the mitochondrial outer 
membrane, the endoplasmic reticulum, and the Golgi apparatus. SMPD5, a MA-
NSM, is the most recently characterized NSM and shares sequence identity with 
SMPD3.45 SMPD5 can be found at the mitochondria and endoplasmic reticulum. 
1.6 Ceramides Stiffen Membranes  
The structure and function of a lipid bilayer is dependent upon the lipids in 
that bilayer. How likely the outer membrane of an autophagosome is to fuse with 
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the lysosomal membrane is partially dependent upon the lipid constituents of the 
two membranes. Whether or not microdomains needed for signaling coalesce 
are determined by the biophysical properties of the membrane as well. Since 
ASM produces ceramides, and ceramides tend to incorporate into lipid 
membrane bilayers, it is essential to understand how such a perturbation affects 
membrane bilayers.  
In the late 1700s, Benjamin Franklin observed that a teaspoon of oil, when 
poured into a pond, spread out on top of the water, covering an area of about 
one-half acre. Oil behaves in this manner due to interactions between the water 
and the oil, more specifically, between the hydrophilic portions of the fatty acids 
that constitute the oil and the polar water molecules. Fatty acids contain a polar 
carboxylic acid attached to a hydrophobic carbon chain. The lowest energy state 
for this system is when the hydrophilic or polar portion of the fatty acid molecule 
is in contact with the water. When this happens, the hydrophobic carbon chains 
are exposed to the air, and the oil molecules will spread out side by side, creating 
an area of oil that is only one oil molecule thick. The very same forces are at 
work in membrane bilayers. 
In 1925 Grendel and Gorter solidified the idea that a fatty layer, two 
molecules thick, covers chromocytes of the blood.49 Around 1960, it was proven 
by electron microscopy that a membrane bilayer, the plasma membrane, 
enveloped cells, allowing for semipermeable diffusion.50 In the early 1970s, the 
fluid mosaic model of the plasma membrane was proposed and is now widely 
accepted.51 This model of the plasma membrane consists of a membrane bilayer 
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with proteins protruding halfway or all the way through the membrane. In the fluid 
mosaic model, lateral lipid diffusion occurs, allowing lipids in an individual bilayer 
to move laterally within that bilayer. Today we know that organelles and other 
structures, such as vesicles or autophagosomes, are enveloped by one or more 
membrane bilayers.52 For example, lysosomes are walled off by a single-
membrane bilayer, and autophagosomes enclose cytoplasmic contents with a 
double-membrane bilayer. 
In full cognizance of other organizing principles, such as van der Waals 
forces, Haamaker constants, and inter- and intramolecular forces, it suffices for 
this work to state that the hydrophobic portions of a lipid-water system will 
aggregate in such a manner as to attain the system’s lowest possible energy 
state. 53 When hydrated, lipids, the primary constituent of membrane bilayers, will 
arrange themselves into lipid bilayers with the hydrophobic regions segregated 
from the hydrophilic regions (Figure 15).54 The hydrophobic fatty acid portion of 
lipids will always be in very close proximity with the fatty acids of the other lipids 
in the system, so the membrane bilayer will always remain intact. As mentioned 
earlier, lipids can move laterally within this “intact” bilayer—a fluid sheet (Figure 
16). These properties allow for the semi-permeability, which is crucial for 
biological processes. Lipids also have many other available motions or degrees 
of freedom within the membrane bilayer. The system of a bilayer is not totally 
ordered, as is a crystal, yet it is not totally disordered, as is a liquid. It is, rather, 
somewhere in between these two extremes and can be described as a liquid-
crystalline system. Whole lipids have the ability to move quickly in two   
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Figure 15.  
Amphiphilic nature of membrane bilayers. 
When hydrated, lipids will form membrane bilayers with hydrophobic fatty acyl 
chains comprising the “middle” portion of the bilayer, leaving the polar head 
groups to face away from the hydrophobic region.  
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Figure 16. 
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Movements of lipids within bilayers. 
Lipids in a bilayer are free to move laterally in the bilayer, but the hydrophobic 
region remains associated with the interior of the membrane during these 
translations (top). Lipids are free to rotate in the bilayer and may move up and 
down with respect to the bilayer normal as well (middle). Lipids have the ability to 
cross the hydrophobic barrier to the opposite leaflet of the membrane (bottom).  
 
 
  
35 
dimensions inside the lipid bilayer and, depending upon the lipid constituents of 
the rest of the bilayer, may or may not readily coalesce with other freely mobile 
lipids inside the same sheet. Therefore, it is possible to have a “lipid raft” inside 
the sheet, enabling lipid composition of the bilayer to influence signaling domains 
required for transduction of extracellular stimuli. Lipids can move in an up and 
down direction perpendicular to the sheet and are able to rotate about this same 
axis (Figure 16). “Flip-flop transition,” or movement of a lipid across the bilayer, is 
possible but is energetically unfavorable (Figure 16).55 Proteins called "flippases” 
transport lipids across the hydrophobic region in response to signaling cues or at 
basal rates.56 Lipids are also free to rotate and traverse the lipid bilayer. Lipids 
are amphiphilic molecules, whereby, the polar head group of a lipid is the 
hydrophilic portion, and the fatty acyl chain is the hydrophobic portion rendering 
the membrane bilayer two lipid molecules thick (Figure 15).  
The composition of lipids that make up the bilayer is a partial determinant of 
membrane function. For example, if all of the lipids in a membrane bilayer were 
stiff, the membrane as a whole would be rigid and have a higher energy barrier 
for fusion—such as an autophagosome fusing with a lysosome. If the lipids in the 
bilayer were less stiff, the membrane as a whole would be more undulating, 
creating a lower energy barrier for fusion. Membrane composition determines the 
stiffness of the bilayer partially via acyl chain order parameters.57 A fatty acyl 
chain is a series of carbons with a carboxylic acid at the end that is able to be 
esterified, thus linking it to a lipid head group. A lipid can be thought of as a head 
group with fatty acyl tails. If the head is held still, then the first carbon in the tail, 
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adjacent to the head group, is “anchored.” The second carbon, attached to the 
first and third carbon, is able to swing through a certain arc of motion. The third 
carbon, attached to the second and fourth carbons, is also able to swing with 
more motion than the second but less than the fourth. Because it is farther down 
the chain and a greater distance from the head, the third carbon has a wider 
range of motion than the second. The same principle transmits all the way down 
the chain through the terminal methyl group (Figure 17). The terminal group has 
the greatest motion, or the least order. An apt analogy is what happens when 
someone holds a chain that is 20 chain links long by their thumb and forefinger. If 
the person’s hand is still, the chain is still and hangs in a straight line. If the 
person moves his or her hand slightly back and forth, the chain will move. The 
chain link that is being held by the thumb and forefinger has no motion other than 
that of the collective thumb-chain-forefinger system movement. The second 
chain link is free to move, but only within the parameters that are set by the 
physical aspects of the chain link, such as its length. The third link will have 
greater motion than the second, and the fourth greater than the third, until the 
final chain link, which will have the greatest motion. 
The motion potential of a unit within a chained structure can alternatively be 
described it in terms of how ordered it is. For example, the last, or greatest 
motion, chain link from the preceding example can be described as being the 
least ordered, the first chain link the most ordered. In liquid-crystalline systems 
the scalar, which is averaged both in space and in time, used to represent order 
parameter of carbons is denoted as SCD.58 This parameter can range from zero to   
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Figure 17. 
 
Acyl chain motions within the bilayer. 
The acyl chains of a lipid constantly move in the hydrophobic region of the 
membrane, with the carbon closest to the head group having the least movement 
and the terminal methyl having the most. Alternatively, the carbon closest to the 
head group has the most order and the terminal methyl the least. Double-headed 
arrows represent possible motions of respective carbons. 
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one-half, with zero representing no order and one-half representing the most 
order. The motion of individual carbons in the fatty acyl tail of a lipid can be 
determined using several different methods, one of which is by solid state 
deuterium nuclear magnetic resonance (NMR).59 Order parameters are 
measured by effectively looking at the orientation of carbon-deuterium bonds in a 
perdeuterated lipid. 
A perdeuterated lipid is one that has had all of the hydrogens removed from one 
of the fatty acyl tails and replaced with deuterium atoms (Figure 18). The van der 
Waals forces are virtually unchanged by the substitution. A signal from the 
deuterium is obtainable via NMR, which allows for the calculation of the order 
parameter of the carbon-deuterium bond for each carbon in the chain, starting 
with the second carbon since the first one is “anchored.” The forces that govern 
intramembrane properties are much greater than intermembrane forces; 
therefore, a small change in order parameter can cause a large change in the 
behavior of the membrane bilayer and how it interacts with other bilayers. 
Intermembrane forces may be much smaller in magnitude, but they are just as 
important. The most abundant lipids in human cells are those of the 
phosphorylcholine (PC) class.38 The majority of lipid components of the outer 
leaflet of plasma membranes that encapsulate cells are of this class. PCs 
comprise a large portion of most intracellular organelle-encapsulating membrane 
bilayers as well. When trying to study the complexly functioning membrane 
bilayer of a mammalian cell, it can be advantageous to model the membrane with 
only lipids to eliminate the confounding factors that exist in cells. Membrane  
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Figure 18. 
 
Perdeuteration. 
A perdeuterated lipid has deuteriums instead of hydrogens on one of the fatty 
acyl chains. This is a very small perturbation to the system that allows the motion 
of the fatty acyl chain to be studied. Deuteriums are in green, carbons are in 
gray, hydrogens in white, nitrogens in blue, oxygens in red, and phosphori in 
fuchsia. 
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bilayers that are created with only purified or synthesized lipids are called 
“model membranes.” The PC class refers only to the head group of the lipid and 
ignores the fatty acyl chains. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), the most abundant, naturally occurring phospholipid lipid, has one fatty 
acyl tail that is 18 carbons long with one double bond between the ninth and 
tenth carbons and another that is 16 carbons long with no double bonds (Figure 
18). Since this is the main lipid in most bilayers, it makes sense to use this as the 
main building block for modeling a membrane bilayer. Justice et al. showed how 
ceramide incorporation into POPC membranes raised the order parameter of the 
POPC lipids with two different ceramides, ceramide 18:1 and ceramide 6:0 
(Figure 19).57 
1.7 ASM Maturation and Subcellular Location 
The first sphingomyelin phosphodiesterase purified was found to hydrolyze 
sphingomyelin into ceramide and phosphorylcholine at an acidic pH and was 
designated SMPD1.44 The corresponding gene, SMPD1, gives rise to two 
different enzymes that perform the same function at two distinct subcellular 
locations.60 The enzyme SMPD1 is post-translationally modified several times, 
ultimately determining where and on which substrates it acts. Although the 
processing of ASM has been extensively studied, it is unclear exactly how this 
enzyme matures into its secreted and lysosomal forms (Figure 20).61 
SMPD1 has an N-terminal endoplasmic reticulum signal sequence, which allows 
for co-translation to occur.61 The endoplasmic reticulum is where the folding 
process of prepro-ASM begins. Further processing of ASM is thought to happen   
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FIGURE 19. 
 
Ceramide incorporation increases order parameters of neighboring lipids. 
From Justice et al. 2014 Biophysical Journal, with permission.57 Smoothed 
profile of order parameter SCD versus position along the sn-1 chain at 30°C for 
(A) POPC-d31 in POPC (solid line), Cer6:0/ POPC (1:10 mol% ceramide:POPC) 
(open circles), and Cer18:1/POPC (1:10 mol% ceramide:POPC) (open squares). 
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Figure 20. 
 
ASM subcellular location. 
ASM is either shuttled to the plasma membrane or to the lysosome. Graphic 
representation of a cell and its organelles. 
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in acidic compartments after the protein has been folded and glycosylated.60 
When ASM is properly folded, there are 16 cysteine residues that are utilized for 
disulfide bonds, making this enzyme susceptible to reducing agents. 
Interestingly, ASM contains one more cysteine that does not make a disulfide 
bridge, and, if this residue is oxidized or deleted, the enzyme has much greater 
activity. As with most secretory proteins, after the stop codon is recognized, the 
endoplasmic reticulum signal sequence is removed and the glycosylation 
process begins. The glycosylation process occurs in the endoplasmic reticulum 
and then may be modified to incorporate the lysosome-targeting mannose-6-
phosphate (M-6-P) tag, a process that happens in the Golgi apparatus before the 
enzyme is shuttled to its final destination. ASM does not always receive an M-6-P 
tag and after glycosylation, ASM will be shuttled and processed (amino acids 
cleaved) outside of the Golgi. Serine 508 phosphorylation and M-6-P tagging 
partially determine the subcellular localization of this protein. If serine 508 is 
phosphorylated, SMPD1 will be secreted in acidic vesicles and is known as 
soluble ASM (Figure 20).62 M-6-P tagging shuttles SMPD1 to the lysosome if 
serine 508 is not phosphorylated and is known as lysosomal ASM. Exactly how 
ASM is transported and processed in unclear. Some groups believe the sortilin 
pathway of sorting saposins might be a shuttling method utilized to transport 
ASM to the lysosome; however, it is believed that the M-6-P pathway is the 
predominant pathway.63 ASM has five out of six possible glycosylation sites 
glycosylated, and these are believed to help ASM endure the harsh acidic 
environment of endolysosomal compartments and may be important to its 
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activity, as ASM activity has been shown to be reduced after treatment with a 
glycosidase.  
While similar in structure and function, soluble and lysosomal ASM have 
some differences other than their subcellular locations. Both require zinc as a 
cofactor; while the activity of soluble ASM can be greatly increased with the 
addition of zinc, lysosomal ASM is slightly sub-saturated with zinc and is thought 
to acquire it during trafficking to the lysosome in early endosomes, late 
endosomes, or possibly in pre-lysosomes.64 Soluble ASM is thought to hydrolyze 
long chain sphingomyelins to produce long chain ceramides; lysosomal ASM is 
thought to produce very-long chain ceramides.60 The first amino acid in the 
mature soluble ASM is histidine 60, while the first amino acid in the mature 
lysosomal form is glycine 66. Although both forms of ASM arise from the same 
gene precursor and both hydrolyze sphingomyelin into ceramide and 
phosphorylcholine, they may have very different signaling effects when activated. 
The molecular weight of full-length prepro-ASM is 75 kDa. This enzyme is 
soon processed, within three hours, to pro-ASM that is 72 kDa and further 
processed to a 65 kDa, mature form after four hours. This processing was 
inhibited when cells were treated with brefeldin A (inhibits transport from ER to 
Golgi), suggesting that processing of ASM occurs after efflux from the 
endoplasmic reticulum. A C-terminally tagged ASM was found to localize with the 
Golgi apparatus rather than with lysosomes, suggesting the mature lysosomal 
form was processed at the C-terminus after exiting the Golgi.61 The processing 
from 72 kDa to 65 kDa is believed to occur in or near an endolysosomal 
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compartment. When ASM is inhibited with a tricyclic amine, the 65 kDa mature 
form is lost and a 52 kDa form appears. Jenkins et al. reported the loss of 
lysosomal ASM activity after pharmacological inhibition of ASM with a 
concomitant reduction of 65 kDa ASM, suggesting that this is the mature 
lysosomal form of ASM. The work contained herein only investigates the mature 
lysosomal form of ASM, which will hereafter be referred to simply as ASM. 
1.8 Functional Inhibitors of ASM 
Imipramine, a tricyclic antidepressant (TCA), has been administered to treat 
depressive conditions for more than half a century.65 It has a different mechanism 
of action as compared to most enzymatic inhibitors.66 Most small molecule 
enzyme inhibitors work through a direct mechanism that reduces the catalytic 
ability of the enzyme. This usually occurs by binding of the small molecule to 
either the catalytic pocket or an allosteric regulatory site of the enzyme. When 
small molecules bind in the catalytic pocket, other entities, such as the substrate 
or cofactors needed for the reaction, cannot bind, thus reducing the catalytic 
activity of the enzyme. Allosteric regulation is when a molecule binds to a non-
catalytic site, which usually changes the conformation of the protein and either 
promotes or decreases activity of the enzyme. Imipramine, on the other hand, 
acts through an indirect mechanism termed “functional inhibition.”67 
Imipramine, a weak base, was used to treat depression as early as 1958. In 
1981 it was determined that a weak base had to have a side chain in order to be 
effective as an ASM inhibitor because weak bases without a side chain had no 
inhibitory effects on ASM.68 In 1994 it was determined that proteolytic 
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degradation was responsible for loss of ASM activity.66 In 2008, steric hindrance 
of the most basic nitrogen was found to determine the effectiveness of the drug.67 
As such, several new functional inhibitors of ASM (FIASMAs) have been 
documented. Since weak bases are not fully ionized when in solution, some of 
their molecules are able to pass through membrane bilayers. If one of these 
molecules passes through the lysosomal membrane, which has a low pH, it will 
become protonated. Once this happens, the molecule can no longer diffuse 
through membrane and, therefore, becomes trapped inside the lysosome—a 
process known as “ion-trapping.” This will interfere with the bonds that adhere 
ASM to the intraluminal side of the lysosomal membrane, and ASM will 
dissociate from the membrane. Once this happens, lysosomal proteases will 
digest ASM, whereby ASM activity is diminished. This is the crux of functional 
inhibition. 
In this research, ASM will also be specifically inhibited with small interfering 
RNA (siRNA) against SMPD1, the gene precursor to ASM. Through binding of 
siRNA to both the five prime and three prime ends of mRNA, the siRNA can 
facilitate degradation of mRNA as well as block translation of mRNA.69 Both 
pharmacological and RNA interference to inhibit ASM, reduce the level of ASM 
protein in the cell, thereby reducing ASM activity. When inhibiting ASM, the 
distinction between ASM activity and the presence of ASM will not be made.  
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1.9 ASM and Autophagy in Disease 
Several diseases that have aberrant autophagic induction and/or autophagic 
flux as part of their pathogenesis have been identified: acute ischemia, acute 
lung injury, aging, Alzheimer’s disease, amyotrophic lateral sclerosis, asthma, 
Barth syndrome, several cancers, cardiovascular diseases, chronic kidney 
diseases, COPD, Crohn’s disease, cystinosis, diabetes, esophageal diseases, 
glomerulosclerosis, hepatic steatosis, Huntington’s disease, idiopathic pulmonary 
fibrosis, myocardial ischemia/reperfusion injury, kidney fibrosis, lysosomal 
storage diseases, mitochondrial diseases, multiple sclerosis, myocardial 
infarction, obesity, Paget’s disease of bone, Parkinson’s disease, polycystic 
kidney disease, pulmonary arterial hypertension, pulmonary hypertension, 
rheumatic diseases, sarcopenia, sepsis, skin diseases, spastic paraparesis, 
pulmonary tuberculosis, ulcerative colitis, ventricular hypertrophy, Vici syndrome, 
viral replication, and viral transmission.70-83 It is unknown whether these diseases 
have dysregulated ASM as well. As mentioned earlier, outside of the devastating 
effects of having little to no ASM activity, not much is known about small, chronic 
variations in the activity of this enzyme. Most studies involving ASM in disease 
have been focused on Niemann-Pick disease or the induction of apoptosis in 
cancer.84, 85 Recently, several publications have linked ASM and abnormal 
autophagic states with somewhat discrepant results.5 “The emerging role of acid 
sphingomyelinase in autophagy,” by Perotta et al. highlights different diseases 
and correlates their ASM expression/activity with autophagic status. It also points 
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out the conundrum of increased as well as decreased ASM activity leading to 
increased levels of LC3B-II.  
Degradative autophagy is thought to play a role in clearing atherosclerotic 
plaques; however, the plaques are rich with 7-ketocholesterol, which decreases 
ASM activity in the lysosome, leading to poor calcium release from the 
organelle.4 Calcium release from the lysosome is required to activate dynein in 
order to move autophagosomes closer to lysosomes, a key step in the 
degradative autophagic process. Alzheimer’s disease (AD) is characterized by 
buildup of plaques in the brain, leading to apoptosis of neurons, memory loss, 
and eventual death.86 Neurons and fibroblasts of AD patients have increased 
ASM activity and a dysregulated degradation mechanism affecting the 
autophagy-lysosome pathway, namely blocked autophagic flux, which causes 
plaques to accumulate and leads to the symptoms described previously.7 
Symptoms of AD in a murine model, characterized by increased ASM activity and 
decreased autophagic flux, were attenuated by a pharmacological ASM inhibitor 
that induced autophagy and restored cognitive function. Emphysema is yet 
another disease that has as part of its pathogenesis hyperactive ASM coupled 
with increased abundance of autophagosomes due to decreased autophagic flux 
that eventually leads to apoptosis and irreversible loss of tissue.87-89 A disease 
with uncontrollable cell proliferation, cancer, is known to have decreased ASM, 
increased autophagy, and apoptosis evasion as part of the pathogenesis.90-92 In 
melanomas, progression stage can be determined by ASM abundance.90 In 
general, it can be postulated that increased ASM activity may eventually lead to 
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blocked autophagic flux, culminating in excessive apoptosis, whereas lack of 
ASM activity may engage pro-survival autophagy. 
1.10 Hypothesis 
ASM contributes to ceramide content of the lysosome, and lysosomally 
produced ceramides are not shuttled to other locations and should exert their 
effects within or around this organelle.93, 94 Downstream metabolite sphingosine 
is able to leave the lysosome and can modulate TFEB signaling through 
calcineurin and modify autophagic signaling. Sphingosine can be further 
metabolized to S-1-P which can change mTOR signaling through S-1-P receptor 
three. Even brief changes in ceramide may alter the biophysical properties of the 
lysosomal membrane, which would have implications in the docking of 
complexes as well as fusion of autophagosomes with lysosomes. 
Since the LYNUS is anchored in the lysosomal membrane, where ASM 
contributes to the ceramide content, and mTOR is a member of the LYNUS, we 
hypothesize that ASM function is required for mTOR signaling and inhibition 
of autophagy during homeostasis. As a corollary, reduced ASM activity is 
sufficient to induce autophagy while concomitantly changing lysosomal 
membrane lipid composition to favor autophagosome-lysosome fusion.  
Since emphysema is a disease with no known cure, exhibits aberrant 
autophagy, has hyperactive ASM as part of its pathogenesis, and eventually 
leads to excessive apoptosis of pulmonary cells, we chose to perform our work 
mainly in ASM-rich primary human pulmonary artery endothelial cells 
50 
(HPAEC).82, 88 Some data were acquired from other human cell types as well as 
a murine model. 
Here, we report that homeostatic ASM inhibition is required for the proper 
function of LYNUS and to inhibit excessive autophagy. Also, ASM activity is 
required to maintain proper sphingosine levels, which may play a role in the 
LYNUS activation status. 
  
51 
Chapter 2. Methods 
2.1 Reagents 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich. 
2.2 Cell Culture 
All experiments were performed in full media unless otherwise stated. HPAEC 
(Invitrogen, C0085C) were cultured in Medium 200 (Invitrogen, M200500), 
supplemented with low serum growth supplement (Invitrogen, S00310). HLMVEC 
(Invitrogen, CC2527) were cultured in an EGM-2MV BulletKit (Invitrogen, 
CC3202). HUVEC, a kind gift from Dr. Mathias Clauss (Indiana University), were 
cultured in VasculLife VEGF Medium Complete Kit (LifeLine, LL0003). THP-1 
monocytes (ATCC, TIB202) were cultured in RPMI (Invitrogen, 11875119), 
supplemented with 10% fetal bovine serum (FBS) (ThermoFisher Scientific, 
sh30910-03HI). Bronchial epithelial cells (BEAS2b) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) with high glucose and pyruvate (Invitrogen, 
11995-073), supplemented with 10% FBS (ThermoFisher Scientific, sh30910-
03HI) and 1% penicillin/streptomycin (Sigma, P4333-100ML). All cells were 
incubated at 37ºC with 5% CO2 and 100% humidity. Experiments were 
performed between 50 and 90% confluency. 
2.3 ASM activity 
Lysosomal ASM activity was measured with an Amplex Red 
Sphingomyelinase Activity kit (Invitrogen, A12220) or radioactivity. Briefly, the kit 
utilizes an indirect two-step reaction that produces a fluorescent readout of ASM 
activity. Cells were washed in ice-cold phosphate buffered saline (PBS) at end of 
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treatment, scraped in ice-cold PBS and centrifuged at 16,000 x g for 10 min. 
Supernatant was removed, and the remaining cell pellet was snap frozen in liquid 
nitrogen. At time of assay, pellets were hydrated with a reaction buffer for 
lysosomal sphingomyelinase activity, incubated with 5 mM sphingomyelin, 2 
U/mL horseradish peroxidase, and 8 U/mL alkaline phosphatase. Kinetic 
fluorescence measurements were read using a wavelength of 590 nm over a 
period of two hours at 37ºC in a SpectraMax m2e microplate reader using 
SoftMax Pro software. 
For the radioactive assay, cells pellets were lysed in 75 µL of a buffer 
containing 25 mM TRIS (pH = 7.6), 5 mM EDTA, 0.2% Triton-x, phosphatase 
inhibitors, and protease inhibitors. To 4 mL of the same buffer used to lyse cells, 
3 µL of 14C-choline methyl sphingomyelin @ 55 mCi/mmol and 0.1 mCi/mL was 
added to create a substrate buffer (1.4 pmol/µL). To 103 µL of the reaction 
buffer, 35 µL of lysate, 12 µL of 0.2 M acetic acid, and 50 µL of substrate buffer 
was added, mixed by vortex and allowed to react at 37ºC for 2.3 hours. To stop 
the reaction, 250 µL of a 2:1 (chloroform:methanol) solution was added and 
vortexed. To this, 800 µL of a 2:1 (chloroform:methanol) plus 250 µL of water 
was added and vortexed. From the aqueous phase, 200 µL was extracted and 
added to 800 µL of MicroScint PS (Perkin-Elmer, 6013631) and radioactivity 
quantified on a Topcount scintillation counter. 
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2.4 Western Blotting 
Cells were washed with ice-cold PBS, gently scraped in ice-cold PBS, 
centrifuged at 16,000 x g for 10 min., supernatant removed and pellets snap 
frozen in liquid nitrogen. Cell pellets were thawed at 4ºC in cell lysis buffer 
containing 1% triton-x (EMD, 9002931), 150 mM NaCl (ThermoFisher, BP3581), 
and 50 mM Tris (pH 7.6) (Invitrogen, 15504020). Cells, at 4ºC, were vigorously 
vortexed five times during a 1 hour period and were centrifuged at 4ºC at high 
speed for 10 min. Supernatant was kept as whole cell lysate. 
Protein concentration was determined using a bicinchoninic assay (BCA) 
(Pierce, 23227). Equal amounts of protein (2-20 µg) were diluted in Laemmli 4X 
buffer (reducing) (Boston Bioproducts, NC9099736) and resolved in Criterion 
12+2 well 4-20% TGX gels (Bio-Rad, 5671093). A semi-dry transfer apparatus 
(Bio-Rad, 1703848) was employed to transfer proteins to a polyvinylidene 
fluoride membrane (EMD, IPVH00010). Membranes were probed with the 
following antibodies: anti-β-actin (A5441), anti-LC3B (Sigma, L7543), anti-
vinculin (Abcam, ab10858), anti-GAPDH (Abcam, ab9485), anti-phospho P70S6k 
(Thr 389) (Cell Signaling Technologies, 9205) and anti-phospho mTOR (Ser 
2448) (p-mTOR) (Cell Signaling Technologies, 5536). Appropriate secondary 
antibodies (goat anti-rabbit/mouse, HRP conjugate) (GE Healthcare, 45001175 
/45001187) were used in conjunction with ECL prime or Luminata Forte 
(ThermoFisher, RPN2232/EMDMillipore, WBLUF0500) for chemiluminescent 
reaction. Images were taken with a ChemiDoc (Bio-Rad) XRS system with 
ImageLab software.  
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2.5 Densitometry 
Density quantification of protein bands in Western blots was performed with 
ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
http://imagej.nih.gov/ij/, 1997-2012). 
2.6 Transfection 
Nucleofector Kits for Primary Endothelial Cells (Lonza, VVPI-1001) in 
conjunction with Amaxa Nucleofector to transfect HPAEC with siGenome siRNA 
(Dharmacon, siGlo/non-targeting pool 1/non-targeting pool 2/SMPD1, 
D0016300205/D-001206-13/D-001206-14/M-006676-01-0020) using program U-
017 per manufacturer’s protocol (1-1.5 million cells per transfection were used). 
Concentration of siRNA ranged from 1-3 µM in up to a volume of 150 µL (inside 
cuvette) just prior to electroporation. After electroporation, cells were added to 10 
mL of full media. Media was changed 18 to 24 hours after electroporation. 
2.7 Quantitative Polymerase Chain Reaction (qPCR) 
Cells were washed with ice-cold PBS, gently scraped in ice-cold PBS, 
centrifuged at high speed for 10 min., supernatant removed and pellet snap 
frozen in liquid nitrogen. RNA was extracted with a GenElute mammalian total 
RNA minikit (Sigma, RTN70-1KT) per manufacturer’s protocol, and cDNA was 
reverse transcribed with a high capacity cDNA reverse transcription kit with 
RNase inhibitor (Applied Biosystems, 4374966). Using SYBR select master mix 
(Applied Biosystems, 4472908) and SMPD1/PGK1 primers (Qiagen, 
PPH02494A/PPH02049A), 25 ng of cDNA was amplified on an ABI 7500 real-
time PCR System (Applied Biosystems). Using Taqman Universal PCR Master 
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Mix (ThermoFisher, 4364340) and TFEB/PGK1 primers (Hs00292981_m1/ 
Hs00943178_g1), 25 ng of cDNA was amplified on an ABI StepOne Real-Time 
PCR System (Applied Biosystems). 
2.8 Immunofluorescence 
HPAEC cells were cultured (125,000 cells per well) on 18 mm glass cover 
slips (VWR, 48380046) residing in 12-well dishes (Costar, 3513) coated with a 
gelatin-based coating solution (Cell Biologics, 6950). After treatment, media was 
removed and formaldehyde (4%) was added to wells at room temperature for 10 
minutes. Cells were rinsed once with PBS (quickly) and washed 3 times with 
PBS (5 minutes) and placed at 4ºC until time of immunostaining. Cells were 
blocked for one hour with PBS containing 5% normal goat serum and 0.3% triton-
x, rinsed once with PBS (quickly) and washed 3 times with PBS (5 minutes), 
exposed to rabbit anti-TFEB polyclonal antibody, Alexa Fluor 555 conjugated 
(Bioss, bs-5137R-A555) in a PBS buffer containing 1% bovine serum albumin 
and 0.3% triton-x, rinsed once with PBS (quickly) and washed 3 times with PBS 
(5 minutes), and mounted with SlowFade Gold Antifade reagent with DAPI 
(Invitrogen, S36939) to microscope slides (ThermoFisher, 12-544-3). Images 
were taken on a Nikon Eclipse 80i microscope. 
BEAS2b that stably express eGFP-LC3B were cultured in 4 well Lab-Tek 
(ThermoFisher Scientific, 154526) slides (50,000 cells per well). After treatment, 
media was removed and formaldehyde (4%) was added to wells at room 
temperature for 10 minutes. Cells were rinsed once with PBS (quickly) and 
washed 3 times with PBS (5 minutes) and placed at 4ºC until time of 
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immunostaining. Cells were blocked for one hour with 10% normal goat serum in 
PBS that contained 0.1% triton-x, they were exposed to rabbit anti-LAMP1 (Cell 
Signaling Technology, 9091; 1:200) in the same buffer, rinsed and washed in the 
same manner as stated above, incubated with Alexa Fluor 594 (ThermoFisher, 
A20185; 1:2,000) in the same buffer, and mounted with SlowFade Gold Antifade 
reagent with DAPI (Invitrogen, S36939) to cover slips (ThermoFisher,12-544-14) 
and imaged on a Nikon Eclipse 80i microscope. 
2.9 Electron Microscopy 
After washing with ice-cold PBS (Fisher, 21-040-CV), cells were fixed with 
glutaraldehyde (Sigma, G7776) and formaldehyde (ThermoFisher, 28908), both 
at 2% in 0.1 M phosphate buffer for 30 min. at room temperature. Cells were 
gently scraped in PBS after two rounds of washing with PBS, centrifuged at high 
speed for 10 min. and given to the Electron Microscopy Core Facility at IU School 
of Medicine for post fixing, embedding, cutting and mounting on slides. Images 
were taken with a Tecnai G2 12 Bio Twin (FEI, Hillsboro) equipped with an AMR 
CCD (Advanced Microscopy Techniques). 
2.10 Differential Centrifugation 
Cells were cultured as above in five 15 cm dishes until 80% to 90% confluent. 
Growth media was exchanged for media warmed to 37ºC containing vehicle or 
treatment. After 30 min., media was aspirated and ice-cold Accutase (10 mL) 
was added to dishes. All reagents and centrifuges were kept at 4ºC from this 
point until storage in methanol. Cells were collected by pipette and spun at 500 x 
g for 5 min. After the supernatants were aspirated, the pellets were suspended in 
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1 mL of PBS and spun at 500 x g for 5 min. After aspirating the PBS, the pellets 
were suspended in solution “B” from Axis-Shield Application S53 plus 
phosphatase and protease inhibitors. An aliquot of these suspensions was 
immediately taken and spun at 500 x g for 5 min. to prepare whole cell samples 
for analysis. After 25 min., each of the 10 samples was homogenized separately 
(30 strokes) in a 1 mL Dounce homogenizer with pestle “B.” Samples were then 
spun at 16,000 x g for 5 min. The supernatant was considered the cytosolic 
fraction, with the remaining pellet being the organelle fraction. The organelle 
fraction was then suspended in 10% v/v with solution “C” as per S53. A 14 mL 
gradient with 2 mL discontinuous steps was made with v/v dilutions of OptiPrep 
as follows: 10% (sample), 12%, 14%, 16%, 18%, 20%, 25% and spun at 150,000 
x g for 20 h. Fractions were collected from the bottom using a 3 mL syringe with 
a 4-inch, 16 gauge blunt needle attached until the 2 mL mark on the syringe was 
reached. Six fractions were able to be collected in this manner with fraction six 
being the first collected. An aliquot of 150 µL from each fraction was removed 
and added to 4X Laemmli (Boston Bioproducts, NC9099736) for Western blotting 
purposes. These fractions were diluted with 10 mL of PBS and spun at 150,000 x 
g for 10 min. The supernatant was decanted and 1 mL of methanol was used to 
prepare the pellet for lipid extraction. The samples were then stored at -20ºC until 
the extraction process. 
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2.11 Lipid extraction and Sphingolipid quantification by LC-MS/MS 
Methanol, water and acetonitrile (HPLC grade) were purchased from Burdick 
and Jackson (Muskegon, MI). Sphingosine (Sph), dihydrosphingosine (DHSph), 
a 17-carbon analog of sphingosine (C17-Sph), sphingosine-1-phosphate (S1P), 
dihydrosphingosine-1-phosphate (DHS1P), a 17-carbon analog of S1P (C17-
S1P), N-acylated (C14:0-, C16:0-, C18:1-, C18:0-, C20:0-, C24:1-, C24:0-) 
sphingosines (Ceramides, Cer), N-heptadecanoyl-sphingosine (C17:0-Cer), N-
acylated sphingosylphosphorylcholines (sphingomyelins, N-12:0-, N-16:0-, N-
18:0-, N-24:1-, and N-24:0-), and glucosylceramides (N-16:0-, N-24:1-, N-24:0-) 
were obtained from Avanti Polar Lipids (Alabaster, AL). N-D3-16:0-
glucosylceramide and N-D3-16:0-lactosylceramide were purchased from Matreya 
LLC (State College, PA). The standards were dissolved in methanol (sphingoid 
base phosphates were dissolved with the addition of a trace amount of 
concentrated hydrochloric acid) and stored at -20°C. L-[U-13C(98%),15N(98%)]-
serine was from Cambridge Isotope Laboratories, Inc (Andover, MA). Pyridine 
(acetylation grade) and acetic anhydride were products of Alltech Associates 
(Deerfield, IL). 
Cellular lipids were extracted with a modified Bligh and Dyer procedure with 
the use of 0.1N HCl for phase separation.95, 96 C17-S1P (30 pmols), C17-Sph (30 
pmols), N-C17:0-Cer (30 pmols), N-12:0-sphingosylphosphorylcholine (12:0-SM, 
100 pmols), N-D3-16:0-glucosylceramide (25 pmol) and N-D3-16:0-
lactosylceramide (25 pmol) employed as internal standards, were added during 
the initial step of lipid extraction. The extracted lipids were dissolved in ethanol 
59 
and aliquots were taken out to determine total phospholipid content as described 
by Vaskovsky et al.97 Samples were concentrated under a stream of nitrogen, 
transferred to autosampler vials, and subjected to consecutive LC-MS/MS 
analysis of sphingoid bases, ceramides, glycosyl/lactosyl ceramides, and 
sphingoid base-1-phosphates. 
2.12 Analysis of sphingoid base-1-phosphates, ceramides, sphingoid 
bases, and sphingomyelins 
Analyses of sphingoid base-1-phosphates, ceramides, sphingoid bases, 
sphingomyelins, glycosylceramides and lactosylceramides were performed by 
electrospray ionization tandem mass spectrometry (ESI-LC/MS/MS). The 
instrumentation employed was Sciex 6500 QTRAP hybrid triple quadrupole linear 
ion-trap mass spectrometer (AB Sciex, Redwood City, CA) equipped with an Ion 
Drive Turbo V ionspray ionization source interfaced with a Shimadzu Nexera X2 
UHPLC system. All lipid molecules and their derivatives were separated using 
Ascentis Express RP-Amide 2.7 µm, 2.1 x 50 mm column and gradient elution 
from methanol:water:formic acid (65:35:0.5, 5 mM ammonium formate) to 
methanol:chloroform:water:formic acid (90:10:0.5:0.5, 5 mM ammonium formate). 
S1P and DHS1P were analyzed as bis-acetylated derivatives with C17-S1P as 
the internal standard employing negative ion ESI and MRM analysis as described 
in Berdyshev et al.98 Ceramides and sphingoid bases were analyzed with C17-
ceramide and C17-Sph as internal standards using positive ion ESI and multiple 
reaction monitoring (MRM) analysis as described in Berdyshev et al.96 To 
facilitate sphingomyelin analysis and to avoid stable isotope overlap between 
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phosphatidylcholines and sphingomyelins, lipids were hydrolyzed using a 
methylamine reagent for 2 hours at 55ºC.99 Reagents were evaporated with a 
nitrogen stream. The residual non-saponified lipids were then dissolved in 0.2 ml 
of methanol and subjected to LC-MS/MS analysis of sphingomyelins. 
Sphingomyelins were detected as positive ions in MRM mode by a transition 
from the corresponding molecular ion to the m/z of 184 (phosphocholine). 
Sphingomyelin quantification was achieved by creating standard curves of 
variable amounts of sphingomyelin standards (N-16:0-, 18:0-, 24:1, and 24:0-
sphingomyelins) versus a fixed amount of N-12:0-sphingomyelin (internal 
standard). Glycosylceramides and lactosylceramides were detected as positive 
ions in MRM mode by a transition from the corresponding molecular ion to the 
m/z of 264 (ceramide ionization). Glycosphingolipid quantification was achieved 
by creating standard curves of variable amounts of glucosylceramide standards 
(N-16:0-, 24:1, and 24:0-glucosylceramides) versus a fixed amount of N-D3-16:0-
glucosylceramide (internal standard). The linearity and the correlation coefficients 
of the standard curves were obtained via linear regression analysis. 
Quantification of sphingolipid molecular species for which there were no 
standards available was performed using best possible approximation from the 
closest available analogs. 
2.13 Mouse Experiments 
All experiments were approved by the IACUC, and animal treatment 
guidelines were followed. Three month-old female Smpd1+/+, Smpd1+/-, or 
Smpd1-/- mice (C57Bl/6 background strain), obtained from Dr. Edward 
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Schuchman and Dr. Erich Gulbins, were used to harvest perfused lungs, which 
were snap frozen in liquid nitrogen.100 Lung tissue was homogenized in the cell 
lysis buffer used for Western blotting. Homogenized tissue was sonicated for two 
seconds at 30% power, centrifuged at high speed, and supernatant was removed 
as whole lung lysate. 
2.14 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism version 6.00 
for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. 
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Chapter 3. Results 
3.1 ASM is required for homeostatic mTOR signaling 
We utilized HPAEC due to their copious ASM activity and dysregulation of it 
in disease.101 We first confirmed the presence of baseline ASM activity in primary 
HPAEC using a fluorometric ASM activity assay (Figure 21). Consistent with the 
literature, we confirmed that ASM activity is profoundly inhibited by imipramine 
with a fluorescent kinetic assay (50 µM; 4 hours; n = 1) (Figure 21). 
Since ASM activity influences lysosomal ceramide content, which may 
contribute to the coalescence of microdomains that may be needed for LYNUS 
docking and signaling, we decided to see if mTOR (a member of the LYNUS) 
activity was changed during ASM inhibition by investigating the phosphorylation 
status of its downstream target, P70S6k.101 Pharmacological ASM inhibition (50-
100 µM; n = 3) significantly decreased the phosphorylation status of P70S6k in as 
little as one hour, for a sustained duration of up to 24 hours, as visualized by 
Western blot and quantified by densitometry (Figure 22A-C). To rule out 
nonspecific effects of the pharmacological inhibitor, we targeted the transcript of 
the sphingomyelin phosphodiesterase gene (SMPD1) with specific siRNA (1-3 
µM, 48-72 hours), which greatly reduced ASM mRNA (n = 5) levels as well as 
activity (n = 3) (Figure 23A and B). Compared to two non-targeting pools of 
siRNA, or to fluorescently labeled siRNA (siGLO), ASM knock-down with SMPD1 
siRNA markedly reduced the phosphorylation status of both mTOR and P70S6k 
proteins, as measured by Western blot and quantified (P70S6k; n = 7) by 
densitometry (Figure 24A and B). Another indicator of LYNUS activation is the   
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Figure 21. 
 
 
Inhibition of ASM with imipramine. 
Kinetics of AmplexRed ASM activity assay in HPAEC exposed to either 
vehicle (water) or ASM inhibitor imipramine (4 hours; 50 µM) in full growth media. 
ASM activity is expressed in arbitrary fluorescent units. Confirmatory data is from 
one experiment. 
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Figure 22. 
 
 
ASM is required for mTOR activity (pharmacological inhibition). 
(A) Representative Western blot of phosphorylated P70S6k relative to vinculin 
(loading control) in HPAEC treated with imipramine (indicated times; 50 µM). (B) 
Representative Western blot and (C) quantification by densitometry of 
phosphorylated P70S6k protein expression in HPAEC relative to vinculin (loading 
control) treated with imipramine (indicated doses; 4 hours). Graph shows 
individual data points of three independent experiments, as well as means and 
standard error of the mean, *** = p ≤ 0.001 (ANOVA with Tukey Post Hoc). 
65 
Figure 23.  
 
 
ASM inhibition with siRNA reduces SMPD1 mRNA and ASM activity. 
(A) Relative quantification of SMPD1 mRNA (ASM gene transcript) by real-
time PCR of HPAEC transfected with siGlo (transfection indicator), non-targeting 
pool 1, pool 2 or SMPD1 siRNA (1-3 µM; 48-72 hours) (B) ASM activity as 
determined by Amplex Red fluorescent and radioactive assays in HPAEC 
transfected with siGlo (transfection indicator), non-targeting pool 1, pool 2 or 
SMPD1 siRNA (1-3 µM; 48-72 hours). Graphs show individual data points of five 
(A) and three (B) independent experiments, as well as means and standard error 
of the mean, *** = p ≤ 0.001 (Student's t-test). 
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Figure 24. 
 
 
ASM is required for mTOR activity (siRNA inhibition). 
(A) Representative Western blot (B) and quantification of p-P70S6k by 
densitometry in HPAEC transfected with siGlo (transfection indicator), non-
targeting pool 1, pool 2 or SMPD1 siRNA (1-3 µM; 48-72 hours). Graphs show 
individual data points of seven independent experiments, as well as means and 
standard error of the mean, ** = p ≤ 0.01 (Student's t-test). 
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phosphorylation status of TFEB, which has more than 10 phosphorylation sites.27 
Indeed, ASM inhibition was associated with a distinct TFEB immunoblotting 
pattern on Western blots (samples were denatured), indicated by loss of the 
“smear” appearance, which is indicative of TFEB phosphorylation seen in control 
conditions, and presence of a lower molecular weight and more resolved band, 
which may indicate a shift in TFEB phosphorylation status (Figure 25).102 This 
pattern is very similar to that of TFEB when cell were exposed to λ 
phosphatase.102 Utilizing immunofluorescence microscopy, we noted 
translocation of TFEB the nucleus following ASM inhibition with imipramine (50 
µM; n = 3) as compared to vehicle-treated cells (Figure 26). These images are z-
stacks from an epi-fluorescent source that have been projected onto a two-
dimensional plane Together, these findings suggest that ASM activity is a 
requisite for LYNUS function. 
3.2 Baseline ASM activity is required for mTOR inhibition of autophagy 
Since mTOR is a well-known inhibitor of autophagy by phosphorylating the 
ULK1 complex, we decided to test the functional impact of baseline ASM activity 
on autophagy.25 Autophagosome abundance was inferred by measuring 
accumulation of LC3B-II. Pharmacological inhibition of ASM with imipramine 
caused a dose-dependent (50-100 µM; n = 3) increase in LC3B-II as detected by 
Western blot and quantified by densitometry (Figure 27A and B). A time course, 
with imipramine at the 50 µM dosage, revealed a sustained effect of ASM 
inhibition on LC3B-II levels for up to 24 hours as detected by Western blot and 
quantified by densitometry (n = 3) (Figure 28A and B). Levels of p62 varied   
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Figure 25. 
 
Decreased phosphorylation of TFEB during ASM inhibition. 
Representative Western blot of TFEB in HPAEC treated with imipramine (50 
µM; indicated amount of time). Note the loss of the “smear” pattern in 
imipramine-treated cells. 
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Figure 26. 
  
 
Nuclear translocation of TFEB during ASM inhibition. 
TFEB immunofluorescence (red) and nuclear staining in blue (DAPI) in 
HPAEC following treatment with imipramine (50 µM; 30 minutes). Note the 
increased abundance of TFEB, both nuclear and cytoplasmic.  
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Figure 27. 
 
ASM is required for mTOR to inhibit autophagy (pharmacological dose 
dependence). 
(A) Representative Western blot and (B) quantification by densitometry of 
LC3B-II protein expression in HPAEC relative to vinculin (loading control), 
following treatment with the ASM inhibitor imipramine (indicated doses; 4 hours), 
compared to vehicle (water). Graph shows individual data points of three 
independent experiments, as well as means and standard error of the mean, *** 
= p ≤ 0.001 (ANOVA with Tukey Post Hoc). 
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Figure 28. 
 
ASM is required for mTOR to inhibit autophagy (pharmacological time 
dependence). 
(A) Representative Western blot and (B) quantification by densitometry of 
LC3B-II relative to vinculin in HPAEC treated with imipramine (50 µM for 
indicated amount of time). Graph shows individual data points of three 
independent experiments, as well as means and standard error of the mean, *** 
= p ≤ 0.001 (ANOVA with Tukey Post Hoc). 
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slightly with no significant differences. Off-target effects were not responsible for 
this phenomenon as inhibition with siRNA against the ASM gene precursor 
SMPD1, led to variable but significant increases in LC3B-II as detected by 
Western blot and quantified by densitometry (n = 14) (Figure 29A and B). These 
results indicate that decreasing ASM activity may induce autophagy. 
3.3 Autolysosomes exhibit degradative potential during ASM inhibition 
The increased LC3B-II abundance following ASM inhibition could be due to 
increased production of autophagosomes or, conversely, the reduced clearance 
of these membrane-encapsulated vesicles.22 To test this point, ASM-inhibition 
experiments in HPAEC were performed in the presence or absence of 
chloroquine, which increases lysosomal pH, diminishes the activity of acidic 
proteases, decreases autophagosome-lysosome fusion, and slows the 
degradation of LC3B-II associated with autophagosomes.103-106 When lysosomal 
degradation was inhibited with chloroquine (50 µM) during ASM-inhibition with 
imipramine (50 µM), we noted a significant increase in LC3B-II above that seen 
during treatment of cells with imipramine alone, suggesting that autophagosomal 
turnover is still occurring and that LC3B-II accumulation is due to increased 
autophagosome formation rather than blocked autophagic flux, although both 
may be occurring to different extents (n = 3) (Figure 30A and B).107-109 Consistent 
with earlier experiments, p62 levels were not significantly increased with 
imipramine-treated cells (Figure 30A and C). We wondered if the lysosomal 
inhibition by chloroquine (50 µM) was too great to see increases in LC3B-II and 
p62 levels above that of chloroquine treatment alone, so we decided to perform   
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Figure 29. 
 
 
ASM is required for mTOR to inhibit autophagy (siRNA inhibition). 
(A) Representative Western blot (B) and quantification of LC3B-II by 
densitometry in HPAEC transfected with siGlo (transfection indicator), non-
targeting pool 1, pool 2 or SMPD1 siRNA (1-3 µM; 48-72 hours). Graphs show 
individual data points of 14 independent experiments, as well as means and 
standard error of the mean, * = p ≤ 0.05 (Student's t-test).  
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Figure 30. 
 
 
ASM inhibition induces autophagy with degradative potential 
(A) Representative Western blot (LC3B-II and p62) and (B) quantification by 
densitometry of LC3B-II protein expression in HPAEC relative to vinculin (loading 
control), following treatment with the ASM inhibitor imipramine (50 µM; 4 hours), 
compared to concomitant treatment with imipramine (50 µM; 4 hours) and 
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chloroquine (50 µM; 4 hours). LY294002 (100 µM) was administered 1 hour prior 
to treatment. Graph shows individual data points of three independent 
experiments, as well as means and standard error of the mean, * = p ≤ 0.05 
(ANOVA with Tukey Post Hoc). (C) Representative Western blot of p62, LC3B-II, 
and vinculin (loading control), following treatment with the ASM inhibitor 
imipramine (50 µM; 4 hours) and chloroquine (5 µM; 4 hours). 
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the same flux experiments using a much lower concentration of chloroquine (5 
µM). Imipramine (50 µM) treatment raised LC3B-II levels above that of vehicle, 
and the co-treatment of imipramine (50 µM) and chloroquine (5 µM) markedly 
increased LC3B-II levels above that of imipramine or chloroquine treatment alone 
signifying more LC3B-II was being generated due to ASM inhibition. (Figure 
30C). Together, these results indicate that ASM is required to inhibit excessive 
autophagy and that ASM inhibition by imipramine induces autophagy in HPAEC. 
We also investigated the autophagic flux in cells with pharmacologically 
reduced ASM function via detection of immunofluorescence in a stable eGFP-
LC3B (green) expressing epithelial cell line (BEAS2b) immunostained with 
LAMP1. Vehicle-treated cells exhibited cytosolic and diffuse green 
immunofluorescence, as expected due to low levels of autophagy, with various 
levels of co-localization with LAMP1-positive (red) endolysosomal vesicles 
(Figure 31). Imipramine treatment increased the abundance of punctate, GFP-
containing autophagic vesicles, consistent with biochemical analysis of increased 
LC3B-II abundance in cells, which overlapped with LAMP1 signal suggesting 
fusion was occurring (Figure 31). Co-treatment with imipramine and chloroquine 
revealed a greater abundance of intracellular GFP punctate vesicles, reflecting 
an increased number of autophagosomes, consistent with the inhibition of 
proteolysis using this weak base (Figure 31). Overlapping signals in this 
treatment from LC3B-II and LAMP1 immunofluorescence produced a yellow 
fluorescence suggestive of intact autophagosome-lysosome fusion in this 
condition. Chloroquine treatment alone, known to raise lysosomal pH, block   
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Figure 31. 
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Autophagosome-lysosome fusion occurs during ASM inhibition. 
Immunofluorescence of BEAS2b expressing eGFP-LC3B (green) and LAMP1 
immunolabeling (red) following treatment with imipramine (50 µM; 4 hours) 
and/or chloroquine (50 µM; 4 hours). Note the red-only immunofluorescence in 
fusion-blocked chloroquine treated cells (lower right), absence of red-only 
immunofluorescence in ASM-inhibited cells (upper right), and bright yellow in co-
treated cells. 
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fusion, and halt degradation, caused green punctae to form but not to the extent 
noted in the co-treatment condition (Figure 31).104-106 Different than imipramine 
alone, the chloroquine alone treatment had many regions of red-only staining, 
indicating a block in autophagosome-lysosome fusion that was not visualized in 
the imipramine-alone-treated cells (Figure 31). Together, these results suggest 
that ASM inhibition signals phagophore initiation and induces autophagy that has 
degradative potential. 
3.4 ASM inhibition of autophagy in multiple cell types 
To determine whether ASM is required to inhibit autophagy during 
homeostatic conditions in other cell types, we tested their response to ASM 
inhibition using similar conditions that triggered autophagy in HPAEC 
(imipramine, 50 µM, 4 hours). Primary human lung microvascular endothelial 
cells (HLMVEC), primary human umbilical vein endothelial cells (HUVEC), 
human monocytic THP-1 cells, and BEAS2b all exhibited similar increases in 
LC3B-II following ASM inhibition as determined by Western blot and quantified 
(BEAS2b) by densitometry (n = 6) (Figure 32A and B). We utilized electron 
microscopy as a complementary method to help understand and visualize 
morphological changes occurring due to ASM inhibition. BEAS2b, cultured under 
control conditions, exhibited very few intra-cytoplasmic autolysosomal bodies as 
determined by small amounts of double membranes (darker) encapsulating 
cytoplasmic material and fusing with lysosomes (arrow; upper left-hand panel) 
(Figure 33).22 In contrast, following ASM inhibition with imipramine (6 hours; in 
low serum), cells accumulated multiple large autolysosomal bodies (Figure 33).  
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Figure 32. 
 
 
ASM inhibition of autophagy in multiple cell types. 
(A) Western blot of LC3B-II and vinculin loading control in primary human 
lung microvascular endothelial cells (HLMVEC), primary human umbilical vein 
endothelial cells (HUVEC), human monocytes (THP-1), or immortalized bronchial 
epithelial cells (BEAS2b) treated with imipramine (4 hours; 50 µM). (B) LC3B-II 
quantification relative to vinculin (loading control) by densitometry in BEAS2b 
treated with imipramine (6 h in 2% FBS; 50 µM). Graph shows individual data 
points of six independent experiments, as well as means and standard error of 
the mean, *** = p ≤ 0.001 (ANOVA with Tukey Post Hoc). 
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Figure 33. 
 
 
Large autolysosomes are formed during ASM inhibition. 
Electron microscopy showing representative images of BEAS2b treated with 
vehicle (left) or imipramine (50 µM; six hours; low serum) (right). Lower panels 
are increased magnification images (lower left is different area than upper left; 
lower right is increased magnification of upper right). Very few autolysosomal 
bodies, as determined by darker limiting membranes of autophagosome fused 
with lysosome were detected in vehicle conditions (arrow; upper right panel). 
Markedly increased amounts of autophagosomes and autolysosomes in various 
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stages of the autophagic process can be seen in the imipramine-treated cells. 
The top two arrows in the upper right-hand panel point to an autophagosome that 
has fused with a lysosome (an autolysosome) and the contents are being 
degraded. The bottom two arrows in the upper right-hand panel point to an 
autophagosome and a lysosome that are about to fuse. Increased magnification 
of the autophagosome about to fuse with a lysosome revealed the actual double 
membrane structure that defines autophagosomes (arrow that points upward in 
lower right panel). The autophagosome contains cytoplasmic contents to be 
degraded while the lysosome is much less electron dense. 
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Different stages of the autophagic process can be seen (Figure 33).22 The top 
two arrows in the upper right-hand panel point to an autophagosome that has 
fused with a lysosome and the contents are being degraded (Figure 33). The 
bottom two arrows in the upper right-hand panel point to an autophagosome and 
a lysosome that are about to fuse (Figure 33). In the lower-right panel, the 
double membrane of an autophagosome is clearly visible (arrow that points 
upward) (Figure 33).22 The autophagosome contains cytoplasmic contents to be 
degraded while the lysosome is much less electron dense (Figure 33).22 
3.5 Rapid autophagosome formation in response to ASM inhibition 
To analyze the sphingolipid content of lysosomes of both vehicle-treated and 
imipramine-treated cells, we inhibited ASM at the shortest time point that gain of 
TFEB mobility and loss of smear pattern was evident (30 minutes) and performed 
a subcellular fractionation. We used isopycnic separation because organelles 
have different ranges of densities thus allowing for the enrichment of certain 
organelles over others (lightest fraction is one and the densest is six) (Figure 
34). The technique that was used yielded both the mature form of cathepsin D 
and LAMP1 in fraction six indicating enrichment for lysosomes in this fraction 
(Figure 34). However, histone h3 (nuclear marker), VDAC (mitochondrial 
marker), and LC3B-II were also found in this fraction indicating that lysosomes 
were not the only constituents of this fraction (Figure 34). Due to the marked 
increase in autophagosomes in this fraction, lysosomal sphingolipid assessment 
was not possible. However, LC3B-II was markedly increased in fraction six and 
present in all fractions of the imipramine-treated cells but was virtually   
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Figure 34. 
 
 
Rapid autophagosome formation due to ASM inhibition. 
Western blot of subcellular fractions (Opti-prep, isopycnic separation) of 
HPAEC treated with ASM inhibitor imipramine (50 µM; 30 minutes). Note the 
abundance of autophagosomal marker LC3B-II in all imipramine-treated 
fractions. Fraction one was the lowest density fraction and fraction six the 
greatest.  
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undetectable in fractions one through five of the vehicle-treated cells and may be 
indicative of newly formed or forming autophagosomes (Figure 34). This 
increase in LC3B-II was not due to different amount of protein loaded because 
LAMP1, a very abundant protein, was found in all fractions with roughly the same 
pattern and abundance in vehicle-treated samples as in imipramine-treated 
samples, indicating that roughly the same amount of protein was used for 
electrophoresis (Figure 34). 
3.6 Sphingolipid changes due to ASM inhibition 
We next used tandem mass spectrometry to measure the effect of ASM 
inhibition on sphingolipid content in the isolated fractions. Fraction six revealed 
the same sphingolipid regulation as all of the other fractions, including whole 
cells and soluble cytosolic portions as determined by LC-MS/MS (n = 4) (Figures 
35 and 36). Consistent with a manuscript by Elojeimy et al. in 2006, which 
treated DU 145 cancer cells with ASM inhibitor desipramine, primary HPAEC 
trended towards increased ceramide and decreased sphingosine content when 
the pharmacological ASM inhibitor was applied as determined by LC-MS/MS(n = 
4) (Figures 35 and 36).110 To test if decreased sphingosine abundance was due 
to the non-specificity of the pharmacological inhibitor or if ASM activity is needed 
for sphingosine production, we analyzed levels of sphingosine by LC-MS/MS in 
HPAEC transfected with non-targeting pool 1, pool 2 or SMPD1 siRNA (1-3 µM; 
48-72 hours; n = 3). Specific inhibition of ASM with siRNA reduced sphingosine 
levels in HPAEC (Figure 37). These results suggest the requirement of ASM to 
maintain appropriate sphingosine levels. 
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Figure 35. 
 
 
Subcellular ceramides increase due to ASM inhibition. 
Total ceramide content of subcellular fractions (Opti-prep, isopycnic 
separation) of HPAEC treated with ASM inhibitor imipramine (50 µM; 30 
minutes). Fraction one was the lowest density fraction and fraction six the 
greatest. WCL stands for whole cell lipids, and SCL stands for soluble cytosolic 
lipids. Graph shows data points for four independent experiments. 
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Figure 36. 
  
 
Sphingosine levels trended towards decrease in all subcellular fractions 
when ASM is inhibited. 
Sphingosine content of subcellular fractions (Opti-prep, isopycnic separation) 
of HPAEC treated with ASM inhibitor imipramine (50 µM; 30 minutes). Fraction 
one was the lowest density fraction and fraction six the greatest. WCL stands for 
whole cell lipids, and SCL stands for soluble cytosolic lipids. Graph shows data 
points for four independent experiments.  
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Figure 37. 
 
 
ASM inhibition with siRNA decreases sphingosine levels. 
Sphingosine levels in HPAEC transfected with non-targeting pool 1, pool 2 or 
SMPD1 siRNA (1-3 µM; 48-72 hours). Graphs show individual data points of 
three independent experiments, as well as means and standard error of the 
mean, * = p ≤ 0.05 (Student's t-test). 
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3.7 Transgenic knockout of ASM increases LC3B-II levels and decreases 
sphingosine levels in lungs of mice 
To investigate if the marked effects of ASM inhibition on autophagy are 
recapitulated in vivo, we probed whole lung lysates of Smpd1+/- mice, which have 
50% the ASM activity as wild-type mice, for LC3B-II.100 These tissues exhibited 
an increase of LC3B-II protein compared to Smpd1+/+ littermates, as determined 
by Western blot and might not be due to the sphingomyelin overload that the 
Smpd1-/- mice exhibit (Figure 38A).1, 111 To test if the known decrease in 
sphingosine seen in primary cells with pharmacological inhibition was present in 
vivo with genetically modified mice and thus not due to the degradation of acid 
ceramidase by the pharmacological inhibitor, we analyzed the sphingosine levels 
in the lungs of the genetically modified mice and compared them to the wildtype 
mice. The sphingosine content was both significantly decreased in the Smpd1+/- 
mouse and drastically reduced in the Smpd1-/- mouse, suggesting that 
sphingosine abundance depends on ASM activity (n = 7, 6, and 5 for Smpd1+/+, 
Smpd1+/-, and Smpd1-/-, respectively) (Figure 38B). 
3.8 Schematic depicting changes due to ASM inhibition 
During homeostatic conditions, ASM functions normally and lysosomal 
homeostasis allows for proper LYNUS signaling that favors protein synthesis 
(Figure 39). ASM inhibition alters LYNUS function by reducing mTOR 
phosphorylation, reducing phosphorylation of mTOR downstream substrate 
P70S6k, translocating TFEB to the nucleus, and inducing autophagy with 
degradative potential (Figure 39).  
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Figure 38. 
 
 
ASM inhibits autophagy in vivo. 
(A) Western blot of LC3B-II from whole lung lysates of genetically modified 
mice (females, three months of age) (B) LC-MS/MS lipid quantification of 
sphingosine (downstream ceramide metabolite) in whole lungs of genetically 
modified mice (females, three months of age). Graph shows individual data 
points from different animals, means and standard error of the mean, * = p ≤ 
0.05, *** = p ≤ 0.001 (ANOVA with Dunnett’s post hoc analysis). 
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Figure 39. 
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Lysosomal ASM contribution to mTOR signaling and autophagy. 
Graphic representation of the lysosomal membrane with LYNUS docked on 
the cytosolic side of the membrane and ASM forming a complex with acid 
ceramidase on the luminal side of the membrane. During homeostatic conditions, 
ASM generates ceramide at a basal rate allowing for proper biophysical 
characteristics of the lysosomal membrane and signaling from downstream 
metabolites. ASM inhibition reduces mTOR phosphorylation, reduces P70S6k 
phosphorylation, translocates TFEB to the nucleus, and induces autophagy with 
degradative potential. 
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Chapter 4. Discussion 
We set out to investigate the hypothesis that ASM function is required for 
mTOR signaling and inhibition of autophagy during homeostasis. As a corollary, 
reduced ASM activity is sufficient to induce autophagy while concomitantly 
changing lysosomal membrane lipid composition to favor autophagosome-
lysosome fusion. With this research, we have discovered a new role for ASM in 
autophagy due to its baseline activity requirement for mTOR activity. Although 
the exact mechanism for this effect remains to be elucidated, it may be related to 
both changes in the lysosomal sphingolipid content and/or reduced sphingosine 
levels. ASM inhibition manifested itself as TFEB translocation with the induction 
of autophagy due to loss of mTOR signaling and decreased sphingosine levels. 
In addition, large, irregular autolysosomes, possibly due to a favorable 
membrane lipid composition and less autophagosome movement due to 
decreased calcium efflux from the lysosome because of ASM inhibition likely 
contributes to the size of these autolysosomal bodies.4 Furthermore, since 
inhomogeneity of EM signal was noted both inside and outside of large, irregular 
autolysosomes, autophagic induction and pleiotropic fusion may be occurring 
simultaneously.22 No loss of lysosomal integrity or cell viability occurred, the 
former assessed by acridine orange staining and the latter measured by 
thymidine incorporation (data not shown). 
One study, by Rossi et al. in 2009, that was performed in a cancer cell line 
that overexpressed LC3-GFP, showed that desmethylclomipramine (DCMI), a 
metabolite of clomipramine which is very close in structure to imipramine, blocks 
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autophagic flux.109 If the increase in LC3B-II due to ASM inhibition in HPAEC was 
due to a blockage in the autophagic flux, much higher levels of LC3B-II would 
have been observed over a 72-hour period. Inducing autophagy by inhibiting 
ASM retains degradative potential in HPAEC. The increase in LC3B-II in the 
Smpd1+/- mice, which have half the ASM activity as their wild type counterparts, 
is most likely not due the sphingomyelin overload and blockage of autophagic 
flux that is seen in the Smpd1-/- mice, which have little to no ASM activity.1, 100, 111 
One limitation in the present study is that autolysosomal degradation was not 
tested using a lysosomal protease inhibitor. It has also been shown that 
autophagosomes move slower without ASM due to decreased calcium efflux 
from the lysosome when this enzyme is not present.108 Autophagic induction with 
less flux may explain the large bodies observed in the electron microscopy 
images. Along with the observations seen by others, we suggest that ASM is also 
needed for mTOR activity and autophagy is induced when this enzyme is 
inhibited both pharmacologically and with siRNA. These effects were also 
observed in an epithelial cell line, endothelial cells of different origins, other lung 
endothelial cells, as well as in monocytes, suggesting ASM control of mTOR may 
be a fundamental mechanism in cells. 
The markedly increased presence of autophagosomes did not allow for 
assessment of lysosomal sphingolipid changes and is another limitation of the 
present study. Subcellular fractionation revealed the rapid manner in which 
autophagosome formation occurs due to ablation of mTOR signaling in response 
to changes in ASM activity. The presence of LC3B-II in the lighter fractions of 
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ASM-inhibited cells and not in vehicle-treated cells, at a 30 minute time point, is 
suggestive of newly formed or forming autophagosomes. Since the markers, 
LAMP1 and mature cathepsin D were present with roughly the same abundance 
in imipramine-treated cells as in vehicle-treated cells, the trend towards 
increased ceramide abundance seen in this fraction may be due to the 
overwhelming presence of autophagosomes. The most profound change in 
sphingolipid metabolism that was observed in response to pharmacological ASM 
inhibition, consistent with previous literature, was a global decrease in 
sphingosine abundance.112  
Here, we show that HPAEC have significantly decreased sphingosine levels 
in response to specific ASM inhibition with siRNA, indicating that ASM activity is 
needed for acid ceramidase to convert ceramide to sphingosine. This effect was 
recapitulated in vivo by significantly and profoundly decreased levels of 
sphingosine in Smpd1+/- and Smpd1-/- mice, respectively. It is unknown whether 
the activity of ASM is needed to produce substrates for acid ceramidase or if its 
presence is needed to form a complex with acid ceramidase for sphingosine 
production.110 It is also unknown if the drop in sphingosine levels is responsible 
for the reduction in mTOR activity. 
Several possibilities exist for the reduction in mTOR signaling due to 
reduction in sphingosine content. First, sphingosine plays a role in calcium efflux 
from the lysosome.113 Hoglinger et al. delivered inactive, caged sphingosine to 
cells and then uncaged the sphingosine with light, which instantly produces 
higher levels of sphingosine intracellularly.113 When sphingosine levels were 
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increased, calcium efflux from the lysosome increased. This led to increased 
calcineurin, which is phosphatase, activity and subsequent dephosphorylation of 
TFEB.114 Also, in cells from Niemann-Pick type C, which mimics Niemann-Pick A 
and B but has a different mechanism, patients were shown to have increased 
lysosomal sphingosine content and exhibited less lysosomal calcium efflux upon 
the uncaging of sphingosine.113 This suggests that the ratio of sphingosine 
outside of the lysosome to that inside of the lysosome plays a role in how much 
calcium exits the lysosome. Acute lowered lysosomal sphingosine and normal 
cytoplasmic sphingosine content may mimic the uncaging of sphingosine and 
subsequent dephosphorylation of TFEB seen by this group. Once sphingosine 
concentrations inside and outside of the lysosome stabilize, the effect may be 
less or even opposite and might be another reason for occasional lower levels of 
LC3B-II in samples with ASM inhibited by siRNA, which would indicate a 
feedback loop. Second, sphingosine itself is known to activate many protein 
kinases and can act without being further metabolized to S-1-P.115, 116 It may be 
possible to decrease mTOR signaling by decreasing sphingosine content—either 
directly or through an unknown signaling cascade. Last, sphingosine can be 
metabolized to S-1-P, which has a plethora of signaling effects.117 The lowered 
sphingosine content may lead to lower S-1-P levels and decreased mTOR 
activation through reduced S-1-P receptor three activation.118 
ASM activity in different human tissues is known to change with age.119, 120 
Both apoptosis and impaired autophagy are associated with ASM 
hyperactivation, which has been implicated in the pathogenesis of multiple acute 
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and chronic diseases, including but not limited to Alzheimer’s disease, acute lung 
edema, and pulmonary emphysema. 5, 7, 101, 121, 122 In general, aging and chronic 
diseases that have hyperactivation of ASM as part of their pathogenesis result, 
eventually, in excessive apoptosis of an organ, such as the brain in Alzheimer’s 
disease or the lung in COPD. This thesis inadvertently contains a translational 
component because it suggests that diseases which have blocked autophagic 
flux as part of the pathogenesis may benefit from therapeutics that inhibit ASM. 
Once tissue loss in the brain of an Alzheimer’s patient or in the lungs of 
emphysema patient occurs, these tissues cannot be regenerated. Blocked 
autophagic flux is part of the pathogenesis of both of these diseases and occurs 
before loss of tissue. It is unknown whether accumulation of autophagosomes is 
the triggering mechanism for tissue loss in either of these diseases, however, 
induction of autophagy with degradative potential may be able to abrogate this 
effect if it is. Administration of tricyclic anti-depressants, with well-known side 
effects that have already been approved by the Food and Drug Administration 
might be able to extend the lives of patients with early signs of these diseases. 
More experiments testing this theory should be performed. 
.  
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Chapter 5. Conclusion 
Our study demonstrates for the first time an important, homeostatic functional 
relationship between ASM and LYNUS in HPAEC. These results indicate a 
requirement for baseline ASM activity in order to maintain sphingosine levels and 
for homeostatic mTOR signaling to occur, inhibiting excessive autophagy during 
normal conditions. These findings, which provide a new link between ASM and 
homeostatic lysosomal function, complement our knowledge of the role of ASM 
hyperactivation during stress. Given the marked effects of ASM inhibition on 
triggering autophagy with degradative potential and blocking mTOR activity, our 
results could be leveraged in clinical conditions before irreversible loss of tissue 
occurs. Reducing ASM activity as a means of triggering fluxing autophagy would 
be pertinent to diseases such as COPD and Alzheimer’s disease, where blocked 
autophagic flux is part of the pathogenesis that occurs before permanent tissue 
loss.7, 87  
The mechanisms by which ASM maintains lysosomal homeostasis remain 
somewhat elusive and can only be postulated. We hypothesize these effects may 
be due to biophysical sphingolipid membrane perturbations that may change 
microdomain characteristics such that LYNUS docking is less favorable and 
fusion of autophagosome and lysosome is more favorable, altered ceramide 
signaling directly to LYNUS via short time scale ceramide flip-flop may be 
happening, indirect signaling by sphingosine itself, or signaling cascades that 
depend on sphingosine, may not be happening in the proper manner. Further 
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studies that can better tease out the lysosomal ceramide content and the effects 
associated with it have to be performed.  
In conclusion, our study indicates that lysosomal ASM is an important 
determinant of homeostatic mTOR signaling and LYNUS function, making this 
sphingolipid metabolic enzyme an important regulator of protein synthesis and 
autophagy inhibition. The clinical implications of these results relate to the 
widespread use of antidepressants that inhibit lysosomal ASM production and 
may give them application in other settings. Furthermore, it may be of interest to 
alter ASM activity to control autophagic induction for therapeutic purposes in 
conditions where these outcomes are desirable. 
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